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Abstract 
Malaria is a significant global disease caused by infection with parasites of the 
Plasmodium genus, which resulted in an estimated 216 million cases and 445,000 deaths 
in 2016 alone. Co-evolution of Plasmodium parasites and their human hosts has shaped 
both genomes for thousands of years. In this thesis I describe my work identifying and 
characterising novel genomic variants and selection signals associated with host-
pathogen interactions in malaria. For the parasite, analysis of the impact of sustained 
sulfadoxine/pyrimethamine (SP) use on the Malawian parasite population (n=220) lead 
to the identification of selection signals associated with SP resistance factors and a novel 
436 bp gch1 promoter region duplication at near-fixation. Next a global approach to copy 
number variation discovery (n=3,110), based on short read sequencing, identified several 
novel and geographically specific variants including large 22.9 kbp duplications of crt in 
West Africa. Finally, an inversion discovery pipeline was developed for a long read based 
approach to inversion detection (n=17). This led to the identification of a novel ‘sandwich 
inversion’ of pi4k in a sample of GB4, similar to inversion-duplication of gch1 in Dd2. 
For human genetics within the context of malaria, I conducted a GWAS with a Tanzanian 
dataset (n=914) and identified novel protective associations, such as for IL-23R and IL-
12RBR2. I also identified novel structural variants (SV) with a short-read sequencing 
based dataset of Tanzanian parent-child trios (n=234) identifying several novel SVs 
associated with blood antigen systems. Near-fixation deletions in SEC22B and BET1L 
were also identified, suggesting an impact on intracellular transportation. Genomic 
variation associated with host-pathogen interactions is diverse, and SVs represent one 
overlooked aspect that requires further investigation. Bioinformatic approaches can help 
identify novel variants but depend upon novel software development, such as those 
described within this thesis (e.g. SV-Pop).  
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1.1 The global and historical impact of malaria 
1.1.1 Malaria as a significant global disease 
Today nearly half the global population, approximately 3.7 billion people, is at risk of 
malaria, with over 90 countries reporting locally acquired transmission. Malaria disease 
burden is not equal across all countries with 15, 14 of which are in sub-Saharan Africa, 
accounting for 80% of the total global burden [1]. Malaria therefore remains a significant 
global health challenge, rivalling the impact of HIV, influenza, and tuberculosis. In 2016 
there were an estimated 216 million cases of infection leading to 445,000 deaths [1]. The 
disease remains one of poverty and infancy with 90% of deaths occurring within Africa, 
where 99.7% of cases are caused by the Plasmodium falciparum parasite [1], and 
approximately two-thirds of deaths are in children below five years of age [1]. Beyond a 
significant human cost, the high mortality and morbidity of the disease has been estimated 
to account for $12 billion of losses per year in Africa alone, further hampering individual 
well-being [2]. 
 
Figure 1: Cases of malaria per capita in 2015. Statistics from the WHO Malaria Report 
2016. Yellow indicates lower rates, whilst red represent higher, grey indicates regions 
with missing data. 
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1.1.2 Aetiology of malaria 
Biologically, malaria is caused by infection with protozoan parasites of the Plasmodium 
genus, primarily Plasmodium falciparum. Infection begins following transmission 
through the bite of a female Anopheles mosquito during a bloodmeal. At least 70 species 
of the Anopheles genus can carry and transmit the parasites [3], but the disease is most 
significantly associated with An. gambiae and An. coluzzii, particularly in Africa [4]. 
Those infected initially appear asymptomatic until the end of an incubation period 
approximately 9-30 days after infection with a median of 11 days for P. falciparum and 
longer for P. malariae [5,6]. Symptoms of uncomplicated malaria are typically flu-like, 
including fever, chills, muscle aches, headaches, cough, and diarrhoea [6], and typically 
occur once parasitaemia has exceeded 100 parasites per μL of blood [7]. Malaria is also 
characterised by paroxysm, a cycle between coldness and fevers occurring just under 
every two days for P. falciparum, every two day for P. vivax and P. ovale, and three days 
for P. malariae [8]. The cyclic nature of the parasite blood stage, in which parasites infect 
and lyse erythrocytes, corresponds to these periodic fevers, with each coinciding with a 
significant increase in merozoite release into the blood [5]. 
Typically, an individual is not infectious to subsequent mosquito bites until at least 7-15 
days after initial infection, upon which a portion of the parasites will have developed into 
the mature gametocyte stage [5]. Eventually an individual level of immunity may be 
acquired, particularly after significant exposure to a variety of parasite strains leading to 
less severe subsequent infections [9]. 
Individual responses to infection can be quite diverse, even prior to any infection, with 
the most extreme forms of response being categorised as severe malaria subtypes. These 
subtypes include hyperlactatemia, severe malarial anaemia, respiratory distress and 
cerebral malaria [5]. Within these subsets, individual risk of death or coma is greatly 
increased [5]. For example, the case fatality rate for treated cerebral malaria is between 
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10-20%, rising to 50% in pregnant women [7]. In contrast, asymptomatic carriage of 
Plasmodium parasites has been reported in several populations [10,11]. 
 
1.1.3 A history of human co-evolution with malaria parasites 
Malaria has been declared as “the strongest known force for evolutionary selection in the 
recent history of the human genome” [12], in large part due to the significant burden the 
disease places upon the global human population today but also due to the sheer length 
of time humans as a species have lived with the disease. The presence of malaria-causing 
Plasmodium parasites for multiple primate species suggests that the disease predates 
Homo sapiens as a species, and a Plasmodium population explosion coinciding with the 
agricultural revolution approximately 10,000 years ago highlights the co-evolution of 
humanity and malaria [13]. 
References to the periodic fevers that characterise malaria have occurred throughout 
history with these being identified as tertian, quartan, subtertian and quotidian by 
Hippocrates in 400 BCE [14]. Malaria has also been highlighted as a potential cause of 
the death of at least four popes (Gregory V 999, Damasus II 1048, Leo X 1521, Sixtus V 
1590) [15], of the famous child-Pharaoh Tutankhamen in 1323 BCE [16], and possibly 
contributing to the fall of the Roman Empire in the 5th century [17]. Notably, the disease 
was so prevalent in Rome and the Roman Campagna during the Middle Ages that it has 
historically been referred to as ‘Roman Fever’. 
Despite the disease clearly existing for millennia, the term ‘malaria’ did not appear until 
the 1800s, instead often being referred to as periodic fevers or ague. Discovery of 
Plasmodium parasites did not occur until Alphonse Laveran identified parasites in patient 
blood smears on the 6th of November 1880, for which he earnt the Nobel Prize in 1907 
[18]. Mosquitos were not identified as vectors of Plasmodium parasites until Ronald Ross 
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demonstrated mosquito-borne parasite transmission in birds in 1897 [19], with human 
transmission via mosquitos being demonstrated two years later in 1899 [20]. 
 
1.1.4 Moving towards global eradication 
Historically, in addition to the tropical regions affected today, malaria was found across 
significant hotspots in the Pontine Marshes of Italy, the British Fenlands and Thames 
Estuary, and Florida, Illinois, and California in the United States of America [21]. Despite 
being classified as a tropical disease, cases have occurred as far north as Archangelsk, 
Russia in 1922-23 during a wider epidemic across the Volga basin [22]. Today, these 
historical regions are considered malaria free due to the removal of potential breeding 
sites, such as the draining of the British Fens in the 18th to 19th Centuries [23] and 
reclamation of the Italian Pontine Marshes in the 1930s [24], except for returning 
travellers, highlighting the feasibility of eradication. Modern examples of successful 
eradication include Paraguay [25], Kyrgyzstan [26], and Sri Lanka [27]; all of which were 
certified malaria free in the last three years. 
Globally, rates of infection have reduced by 37% and deaths by 60% between 2000 and 
2015 [28]. Yet despite this success, elimination efforts are increasingly at risk of being 
undermined by various independent emergences of resistance to classic antimalarials such 
as chloroquine, and more recent artemisinin-based combination therapies (ACTs). 
Furthermore, it can be argued that those regions where elimination has been possible are 
so-called ‘low hanging fruits’ with elimination from the remaining, more endemic regions 
being significantly more difficult. 
Looking towards future eradication, in 2016 the WHO identified 21 countries, including 
Mexico, China, and South Africa, with the potential to eliminate malaria by 2020 [29].  
However, those countries within this E-2020 initiative highlights these regions as bearing 
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relatively low burden with none existing within West, Central or East Africa where most 
of the malaria burden exists. 
The current situation partially reflects previously optimistic malaria control programs 
such as the Global Malaria Eradication Programme of the 50s and 60s. Whilst initially 
successful, particularly in Europe and Northern America, the project ultimately failed to 
effectively eliminate malaria with resurgence of infections occurring in many regions. 
Whilst success was initially found primarily through the residual spraying of the 
insecticide DDT, the programme was ultimately undermined by a variety of factors 
including the rise of anti-malarial resistance in South Asia [30], insecticide resistance to 
DDT, and the reduction in funding by some countries [31]. 
As we move again towards the potential elimination of malaria, an emphasis is needed on 
a diverse range of complementary strategies which consider ecological and chemical 
control of disease vectors, novel approaches to drug surveillance and policy, the role of 
human genetics, and a strong emphasis on local health infrastructure empowered by rapid 
diagnosis tests (and an awareness of emerging ‘resistance’ to these). 
Control and eradication efforts must be responsive to adapting parasite populations and 
tailored to their regional differences. Comprehensive surveillance and characterisation of 
global Plasmodium genomics – a major component of this thesis - represents one key 
aspect to a modern, empowered approach. Strides can also be made in the detection of 
asymptomatic human carriers and individuals at greater risk of severe reactions. In 
general, solutions to these challenges demand an ever-greater understanding of the 
biological mechanisms relating to malaria in both humans and parasites, particularly those 
underpinning the host-pathogen relationship. 
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1.2 The diagnosis, treatment, and control of malaria  
1.2.1 Diagnosis of malaria infection 
Confirmation of parasitaemia is typically required for a malaria diagnosis and can either 
be performed via a microscope, rapid diagnosis test, or PCR-based approaches. 
Examination of stained blood smears under a microscope is the gold standard approach 
which allow for both confirmation of infection and identification of the specific species. 
This form of evaluation requires both access to laboratory facilities and a skilled examiner 
[32] with misdiagnosis being possible due to some shared features between species.  
Rapid diagnosis tests (RDTs), in which a blood sample is applied to an antibody treated 
dipstick, are more suitable for fast diagnosis in the field [32]. Multiple types of RDTs 
exist though the most common targets include the P. falciparum specific gene histidine 
rich protein II (Pfhrp2) and the pan-species lactate dehydrogenase (LDH) [7]. Efficacy of 
these tests are generally high but can be reduced by the presence of genetic variation of 
the target proteins [33]. Newer PCR-based approaches are also in development, with these 
allowing a combination of higher sensitivity with the ability to identify specific variants 
associated with drug resistance or mixed infections, though they are currently 
inappropriate for use in the field [32,34]. 
 
1.2.2 Current approaches for treatment and control 
Approaches towards the control, elimination and treatment of malaria are relatively 
diverse and include several social, physical and biochemical interventions. Primarily 
these can be summarised into either prevention of transmission through mosquito control 
or source reduction, prevention of disease through vaccination, or chemical prophylaxis, 
and treatment following infection with several antimalarials. 
One major component of preventative care is the application of insecticide-based, 
mosquito-targeted approaches to reduce the number of possible transmission events. 
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Insecticide-treated mosquito nets (ITNs) and more recently introduced long-lasting 
insecticide-treated nets (LLINs), primarily act as physical barriers between humans and 
mosquitoes reducing parasite transmission, with the application of insecticides boosting 
their efficacy [35]. Similarly, indoor residual spraying (IRS), the internal spraying of 
households with insecticides such as DDT or pyrethroids to kill mosquitoes is another 
successful intervention. IRS has been found to be effective at reducing malaria incidence 
in a 2010 Cochrane review [36], though only if 80% of residences within an area are 
covered by the intervention [37]. Whilst effective, the insecticides applied to bed nets 
typically only remain for approximately up to a year for ITNs and at least three years for 
LLINs, with this being reduced if those nets are actively washed or used inappropriately 
[38], one example being their occasional misuse as fishing nets [39]. 
Mosquito control aimed at reducing transmission can also benefit from the active removal 
of mosquito breeding sites, a technique known as source reduction [40]. Anopheles 
mosquitoes have a diverse range of specific breeding site preferences, but generally 
require bodies of standing water for their breeding sites [41]. The removal of potential 
breeding sites can therefore drastically reduce mosquito populations and with it the 
transmission of malaria, as was historically seen in Europe. Large scale reshaping of 
landscapes is not necessarily required for successful source reduction interventions. 
Anopheles breeding sites are often man-made, with one study considering two major 
urban sites in Ghana finding that 74.5% were non-natural [42]. Measures can also be 
integrated into more broad scale improvements of local infrastructure [43]. 
RTS,S is the first, and currently only, available malaria vaccine and was approved by 
European regulators in July 2015, having begun development in the 1980s, [44]. As a 
recombinant vaccine it contains circumsporozoite protein (CSP) derived epitopes [45], 
CSP being a protein typically associated with sporozoite adhesion to and invasion of 
human liver cells [46]. The effectiveness of the vaccine is boosted by co-expression with 
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hepatitis B surface antigen [47], yet despite this RTS,S has a relatively low efficacy 
(4.4%) [48]. The development of alternative vaccinations and therefore the identification 
of novel vaccine candidates therefore remains critical. 
Alongside patient treatment, antimalarials are utilised for preventative approaches, 
particularly for high-risk groups such as pregnant women or travellers from non-endemic 
regions. Seasonal malaria chemoprevention (SMC), the seasonal application of 
antimalarials, typically a combination of sulfadoxine-pyrimethamine (SP) and 
amodiaquine, across the Sahel sub-region was initially recommended by the World 
Health Organisation in 2012 [49] and has since been shown to be effective at reducing 
incidence of malaria by 60% [50]. 
Similarly, intermittent preventative treatment in pregnancy (IPTp), the application of a 
full course of antimalarials, typically SP, from the second trimester has also been 
recommended by the WHO across Sub-Saharan Africa from 2012 [51]. Pregnant women 
represent a key risk group due to significantly reduced level of naturally acquired 
immunity [52]. It has since been adopted across 36 African countries, despite a lag in 
expansion in recent years [53]. 
Application of antimalarials is currently the most effective treatment for malaria, though 
the emergence of resistance threatens to undermine this efficacy. One classic example is 
chloroquine, which saw widespread use until the emergence of resistance led to its 
replacement by alternative treatments such as SP, and more recently artemisinin 
combination therapies (ACTs). 
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Table 1: Summary of antimalarial introduction and resistance. Dates sourced from 
"Global defence against the infectious disease threat" (WHO 2003) 
Antimalarial Introduced Resistance Associated Genes 
Chloroquine 1945 1957 crt 
Mefloquine 1977 1982 mdr1 
Proguanil 1948 1949 dhfr 
Atovaquone 1996 1996 mt-cytb 
Sulfadoxine/Pyrimethamine 1967 1967 dhps, dhfr, gch1 
Artemether-lumefantrine 2006 Emerging kelch13 
 
1.2.3 Chloroquine & Quinine-derived Drugs 
Chloroquine was initially discovered in 1934 as a synthetic alternative to quinine [54], 
the traditional antimalarial originally isolated from ‘Peruvian bark’, derived from several 
species of tree from the Cinchona genus, in 1820 [55]. The relative safety, efficacy, and 
affordability of chloroquine quickly led to its widespread use, though the rise of resistance 
eventually led to its gradual withdrawal. Recently chloroquine-susceptibility has begun 
to re-emerge in several Plasmodium populations though chloroquine use is still generally 
prohibited [56], except for some Central and South American countries where resistance 
is especially rare, if not entirely absent, such as Mexico, Panama, Haiti, and Argentina 
[57]. 
The mechanism of action for chloroquine against Plasmodium parasites is not fully 
characterised but thought to involve disruption of the parasite’s haem detoxification 
pathway, located within its digestive vacuole [58]. Digestion of the human host 
haemoglobin by the infecting parasite produces haem as a by-product. Accumulation of 
haem is toxic to the parasite, and typically converted to less toxic haemozoin within the 
parasite digestive vacuole [59]. Chloroquine disrupts the haem detoxification process 
after passing, non-polarised, into the low pH digestive vacuole through simple membrane 
permeability, wherein it becomes protonated and resilient to efflux [60]. Once inside the 
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vacuole, chloroquine concentrations gradually increase, accelerating its binding to 
haematin and leading to the build-up of toxic haem monomers. Excess levels of haem 
increase the permeability of the vacuole membrane, resulting in the death of the parasite. 
Notably mutant parasites without the enzymes required for haemoglobin proteolysis, and 
therefore without the ability to produce haem, have previously been shown to be resistant 
to chloroquine [61]. 
Chloroquine resistance first emerged in Asia and South America in the 1950s and 60s and 
has emerged independently at least four times including in Southeast Asia (from which it 
spread to Africa), Papua New Guinea, and twice in South America [62]. Since its initial 
emergence, chloroquine resistance has spread across the globe, though it has since 
reduced in several areas, including Africa, following restrictions upon chloroquine use as 
a front-line anti-malarial [63]. Genetic variants of multi-drug resistance gene 1, mdr1, and 
chloroquine resistance transporter, crt are typically associated with chloroquine 
resistance. For mdr1, its decreased expression has been associated with resistance, 
suggesting that its protein product aids the active transport of chloroquine into the 
digestive vacuole [64]. In contrast, the K76T variant of crt is associated with a reduced 
chloroquine concentration within the parasite digestive vacuole, suggesting that the 
wildtype CRT protein actively transports the drug out of the organelle and that the K76T 
variant reduces the protein’s efficiency [65]. The two genes would therefore appear to 
complement one another, with their combination enhancing resistance. 
 
1.2.4 Sulfadoxine/Pyrimethamine (SP) & Antifolate Compounds 
The synthesis of folate cofactors from folic acid through the Plasmodium folate pathway 
is critical to the supply of various molecules required for DNA synthesis [66] and consists 
of a handful of conserved proteins including DHFR, DHPS, and GCH1 [67]. Antifolate 
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drugs target this pathway through various targets and mechanisms and include proguanil, 
dapsone, sulfadoxine, and pyrimethamine [68]. 
SP is one example of an antifolate combination therapy first introduced in the early 1980s 
following the emergence of chloroquine resistance, its relative safety makes it one of the 
most widely used antifolate antimalarials [69]. Whilst sulfadoxine competitively inhibits 
dihydropteroate synthase (DHPS), encoded by dhps, pyrimethamine inhibits 
dihydrofolate reductase (DHFR), encoded by dhfr [70], both being key members of the 
folate pathway [67]. 
Resistance to SP first emerged in the late 1980s in Southeast Asia, before spreading to 
Africa and South America, leading to a shift of its use towards intermittent preventative 
treatments during pregnancy and infancy [71]. Unsurprisingly, this resistance is 
associated with variants of the respective target genes with single nucleotide 
polymorphisms in dhps, such as 450E [72], and dhfr, including 108D and 164L [73]. 
Additional resistance has been associated with whole gene duplication of GTP 
cyclohydrolase 1, gch1, with increased expression counter-balancing the fitness cost of 
dhps and dhfr point mutations [74]. Notably GCH1 lies upstream of DHPS and DHFR 
within the folate pathway, suggesting that duplication of gch1 may act to compensate for 
fitness costs associated with dhps and dhfr mutation [75]. 
 
1.2.5 Artemether/Lumefantrine & Artemisinin-based Combination Therapies 
(ACTs) 
Artemisinin first emerged as a potential anti-malarial during the Vietnam War, when the 
increasing failure of chloroquine led to requests from North Vietnam to China for an 
alternative therapy. This resulted in ‘Project 523’, one component of which evaluated folk 
remedies associated with plants of the Artemisia genus, from which the artemisinin 
compound emerged [76]. An active push away from artemisinin monotherapies began in 
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2014 following emerging resistance [77]. Today ACTs are the recommended first line 
anti-malarial for uncomplicated P. falciparum malaria. 
Artemether-lumefantrine is the most commonly used artemisinin-based combination 
therapy [78]. Whilst effective, the mechanism of action is unconfirmed, with one leading 
hypothesis suggesting that artemisinins are activated by interaction with haem and 
iron(II) oxide within infected red blood cells, resulting in the production of free radicals 
which kill the intracellular parasite through oxidative stress [79,80]. 
Initial reports of artemisinin resistance first emerged, as reports of significantly slower 
parasite clearance, in the 2000s [81]. Since then point mutations in the propeller domain 
of kelch13 have acted as a reliable indicator of this reduced clearing in Southeast Asia 
[82]. Decreased susceptibility has also been associated with variants of atpase6 in French 
Guiana [83]. In general, resilience to artemether-lumefantrine has been restricted to 
Southeast Asia whilst resistance to other forms of ACTs, such as artesunate-sulfadoxine-
pyrimethamine (AS+SP), have emerged in India, Somalia, Sudan, Afghanistan, Iran, 
Pakistan and Yemen, leading these countries to switch to artemether-lumefantrine [84]. 
Identification of novel drug resistance associated variants has greatly benefited from 
whole genome-sequencing approaches that utilise computational methods such as 
association and selection. For example, the role of kelch13, and specifically SNPs 
including the C580 allele, as markers for artemisinin resistance were discovered through 
a genome-wide association study [85]. Previous approaches, on more limited custom SNP 
arrays, have allowed for the identification of signals of selection for crt resistance with 
integrated haplotype score (iHS) scans for positive selection on limited arrays [86], future 
higher resolution genome-wide approaches present the opportunity to widen this net to 
detect further antimalarial resistance signals at an earlier stage. 
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1.2.6 Existing and Emerging Resistance 
Some form of resistance or reduced efficacy exists in the field for almost all known 
antimalarials, with resistance even emerging for newer treatments such as artemisinin-
based combination therapies. Whilst the speed of emergence for resistance varies, 
historically the time between drug introduction and resistance has been relatively short 
with resistance to chloroquine appearing just over 20 years after initial use [87] but less 
than one year for SP [88]. Curiously resistance to chloroquine, SP and ACTs all initially 
emerged along the Thailand-Cambodian border relatively quickly [81,89]. This likely 
stems from a combination of early access to artemisinin monotherapies from China during 
the Vietnam war, infection being limited to the non-continuous exposure of a working 
age and transient population of forest workers, and a health infrastructure weakened by 
three decades of war. Further successful WHO surveillance has ensured that resistance 
was spotted early even if it had earlier emerged independently elsewhere. Mathematical 
modelling has also suggested that emerging drug resistance is less likely to become 
established in lower transmission settings, such as Southeast Asia, than high transmission 
settings, such as sub-Saharan Africa, due to a lower degree of in-host competition 
between Plasmodium strains [90]. 
Selection for specific parasite variants that convey increased survivability in response to 
human interventions is not exclusive for antimalarials. The World Health Organisation 
now recommends that all malaria cases be confirmed by a rapid diagnosis test (RDT) [91] 
but ‘resistance’ is developing for these. Specifically, the emergence of genetic variants 
within the target parasite proteins leads to false negatives, thereby causing inappropriate 
non-application of antimalarials. One key example is deletions in Pfhrp2/3 that have been 
shown to cause false positive test results and therefore risk lack of intervention increasing 
parasite survivability [92]. 
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Genetic variants conveying resistance range of small single base changes (SNPs) such as 
crt K76T to larger structural variants (SVs) such as the duplication of mdr1 in mefloquine 
and lumefantrine resistance [93]. Speed of emergence and persistence of resistance also 
varies (CQ slow to appear, fast to leave; SP fast to appear, slow to leave) which may 
reflect the underlying complexity of resistance mechanisms. For example, resistance 
through one specific form (such as K76T for chloroquine) may be less likely to occur and 
faster to leave (as one specific SNP is required) compared to SP resistance (multiple SNPs 
convey resistance, fast to acquire any, slow to remove all). The role of compensatory 
variants is also key as many resistant variants may bear a fitness cost that additional 
variants may compensate for. One possible example is the duplication of gch1 as 
compensatory for dhfr and dhps mutations in SP resistance [75]. 
 
1.3 The role of Plasmodium parasites 
1.3.1 Species of Plasmodium 
The Plasmodium genus is broad and consists of over 200 species [94], of which the vast 
majority infect a range of non-human hosts including other primates [95], various 
mammals [96], several reptile species [97], and over 150 that infect birds [98]. At least 
five Plasmodium species (P. falciparum, P. vivax, P. malariae, P. knowlesi, and the two 
P. ovale subspecies) specifically cause malaria in humans with almost all cases being 
caused by Plasmodium falciparum, particularly in Africa where they account for 99.7% 
of cases [1]. Notably P. falciparum is phylogenetically distinct from the other human 
infecting Plasmodium species, clustering closer to the chimpanzee infecting P. 
reichenowi [99]. Their genomes also contain some disease-relevant genes not found in 
other species, such as the Rh2a and Rh2b gene pair required for erythrocyte invasion 
[100]. 
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Outside of Africa, Plasmodium vivax is more prevalent, accounting for 64% of cases in 
South America, over 30% in Southeast Asia, and over 40% of cases in the Eastern 
Mediterranean region [1]. Infection with P. vivax or P ovale, is also characterised by an 
additional dormant liver ‘hypnozoite’ stage, which can allow an infection to ‘hibernate’ 
for multiple years before symptoms emerge, making this stage a unique target for drug 
discovery [101]. 
The more benign P. malariae, the zoonotic P. knowlesi, and the two P. ovale sub-species 
cause very few cases of malaria. In total, these account for less than 1% of global cases 
[1]. Though these cases may be underestimated due to common mischaracterisation as P. 
falciparum or P. vivax infections due to clinical assumption or visual similarities between 
P. ovale and P. vivax when viewed through a microscope, for example due to the presence 
of shared features such as Schüffner’s dots [102]. Rates of misdiagnosis are often quite 
significant, with one study based in China reporting false positive rates for P. ovale and 
P. malariae that exceeded 70% [103]. 
A minority of other Plasmodium species have also recently been implicated in rarer cases 
of human infection. These include a 2014 report of a P. cynomolgi infection in Peninsula 
Malaysia [104], and a 2015 report of P. brasilianum infection in the Venezuelan Amazon 
[105]. Typically, such cases were initially misidentified as other forms of Plasmodium, 
suggesting that additional cases of infection with rarer Plasmodium spp. may have been 
overlooked. Other simian Plasmodium species, in addition to P. knowlesi, have also been 
demonstrated as capable of infecting humans, including P. schwetzi [106], P. inui [107], 
and P. simium [108] with cases of the latter being increasingly common in south-eastern 
Brazil, possibly due to more accurate distinction between cases of P. vivax and P. simium 
infection. For example, one recent study found that most cases of malaria in the Rio de 
Janeiro Atlantic Forest are caused by P. simium, leading to the development of specific 
detection methods to reduce false classification as cases of P. vivax infection [109]. 
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1.3.2 Plasmodium Life Cycle 
Plasmodium parasites experience a particularly complex life cycle with multiple stages 
across at least two hosts; a female mosquito and a secondary host, humans in the case of 
malaria. Initially, the parasite will enter the human host from the mosquito salivary 
glands, via a bloodmeal, as a sporozoite. These sporozoites then infect hepatocytes within 
the liver, in which they rapidly replicate forming schizonts that rupture to release the 
merozoite stage parasite (here P. vivax and P. ovale may also enter a dormant hypnozoite 
stage). Those merozoites will then enter the blood and infect erythrocytes, entering a 
‘ring-shaped’ trophozoite stage followed by further asexual replication within schizonts 
until rupturing the host erythrocyte and re-entering the blood. This cyclic process results 
in the anaemia and periodic fever commonly associated with malaria, and further accounts 
for the delay in onset of symptoms following infection. Approximately 1.0% of merozoite 
parasites will progress to the sexual gametocyte stage [110]. Those gametocytes will 
remain within erythrocytes until taken up into a new mosquito host, in the gut of which 
they are released to form zygotes and eventually ookinetes that embed into the gut 
membrane [111]. Once in the gut membrane, ookinetes develop into oocytes that divide 
multiple times into sporozoites that migrate to the mosquito salivary gland from which 
they can be injected into a new host during a bloodmeal [112]. 
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Figure 2: Life cycle of the Plasmodium falciparum parasite. Schematic diagram 
demonstrating the key life cycle stages and their locations within each host for the P. 
falciparum parasite. 
 
1.3.3 The genomics of P. falciparum 
Efforts to sequence the whole P. falciparum genome began in earnest in 1996 [113] with 
the first draft being completed six years later in 2002 [114]. The core nuclear genome is 
23.3 Mbp in size, split across 14 chromosomes and contains approximately 5,300 genes 
with a mean length of 2.3 kbp [114]. The genome is notable for its significant AT-rich 
nature, with a GC content less than 20% [114]. 
P. falciparum also contains two forms of non-nuclear DNA in the form of a 
mitochondrion, and the apicoplast, an organelle unique to the Apicomplexa phylum with 
roles in metabolic pathways such as haem biosynthesis and fatty acid synthesis [115]. Of 
these, the mitochondrion is 6 kbp in size, and dependent on nuclear genome for tRNA 
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synthesis [114]. In contrast the apicoplast is far larger, at 34 kbp, and able to encode its 
own tRNAs [114]. Evolutionarily, the apicoplast is chloroplast-like and thought to be the 
result of secondary endosymbiosis [116], though it has since lost its photosynthetic 
capabilities. 
Survivability within the host is enhanced through antigenic variation of surface proteins 
produced by families of highly repetitive genes. These include families of highly variable 
life stage-specific surface antigens, such as the var family [117], the trophozoite-specific 
adhesins rifin family [118], and the schizont stage stevor family [119]. Members of these 
genes recombine to create antigenic diversity on the surface of parasite-infected red blood 
cells (iRBCs) enhancing immune evasion. Typically, loci for members of these gene 
families are excluded from standard short read based analysis due to issues resolving their 
proper sequencing given their highly repetitive nature and their presence within poorly 
resolved subtelomeric regions. 
All three highly variable gene families are also members of the P. falciparum exportome, 
which also includes PHIST-domain containing proteins and ring-infected erthrocyte 
surface antigen (RESA) [120–122]. As the name suggests, proteins encoded by these 
genes are exported from the infecting P. falciparium into its host. Members of the P. 
falciparum exportome are therefore key to several host-pathogen interactions with their 
expression being vital for infection of host cells and supporting evasion of the host 
immune system [123,124]. 
Many, but not all, exported P. falciparum proteins contain the PEXEL (or host-targeting, 
HT) motif (R/HxL/IxE/D/Q, where x is any amino acid), allowing bioinformatic 
prediction of exported genes due to the presence of this motif [120,125,126]. Another 
such motif of bioinformatic interest is the TATA (or Goldberg-Hogness) box, which 
identifies likely promoter regions in eukaryotes and archaea [127]. 
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1.3.4 Variation in P. falciparum reference strains 
There exists a significant number of established lab-adapted P. falciparum reference 
strains upon which analysis has taken place, the majority of which were isolated in the 
early 1980s. The primary reference strain for P. falciparum is 3D7, whose African origins 
were only elucidated in 2014 [128], despite having been isolated in the Netherlands in 
1981 from an individual whom had never been abroad [129]. 
Other prominent reference strains include 7G8, a 1981 clone of IMTM22 originally 
isolated from a 12-year-old male from Manaus, Brazil in 1980 [130], and HB3, a 1983 
clone of H1 originally isolated in Honduras in 1980 [131]. 
One particularly lab-adapted strain is Dd2, a 1996 clone of W2-MEF derived from 
W2pMCII following six months of selection for mefloquine resistance which was itself 
derived from 12 months of mefloquine resistance selection of a culture originally isolated 
from a Lao refugee in 1980 [132,133]. Dd2 is particularly noteworthy for featuring a 
triplication of gch1, which has been associated with SP resistance [70]. 
Lab and computational-based analyses of these strains has facilitated the identification 
and characterisation of genomic diversity, virulence, and anti-malarial resistance but have 
tended to focus on specific lab strains or restricted geographical regions. More recently 
analyses have shifted from strain-specific contexts to large global datasets. One notable 
example is the Pf3k project which seeks to take an international approach to the 
collection, collation, and analysis of P. falciparum samples [134]. Release three of this 
project contained 2,512 samples from 14 countries [135]. This shift towards larger 
datasets has led to a greater demand for bioinformatic approaches to big data processing 
and analysis. 
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1.4 Human genetics in the context of malaria 
1.4.1 Determinants of diversity of human response to infection 
Individual responses to infection with Plasmodium parasites are diverse due to a 
multitude of environmental, genetic, and immunological factors. Whilst some infected 
individuals may present as asymptomatic, others can experience combinations of severe 
subtypes such as hyperlactatemia, respiratory distress, and cerebral malaria [6]. These 
severe malaria subtypes being almost exclusively caused by P. falciparum infection 
[136]. Some of this diversity reflects expected risk factors for any communicable disease. 
For example, higher severity is often associated with being especially young or old [137], 
pregnant [138] immunocompromised, or immunologically unfamiliar to infection. Some 
diversity also reflects random exposure to particularly virulent strains or regions with 
higher transmission. 
It is also possible to obtain a level of acquired immunity to infection through sustained or 
repeated infection with Plasmodium parasites [9]. The presence of an acquired level of 
resistance suggests the circulation of human immunological factors, pathways or 
mechanisms that, if correctly identified, could underpin efforts towards new antimalarials 
or new vaccine candidates. 
Disease-linked features often represent confounding factors that must be appropriately 
controlled for in statistical analyses, such as genome-wide association studies, when 
seeking to identify novel causal genetic variants. These can include gender, where it has 
been suggested that women (particularly pregnant women) are at higher risk [138], and 
age, with this possibly reflecting the time-lag associated with developing an acquired 
immune response [137]. 
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1.4.2 Severe malaria subtypes 
A diversity of severe malaria subtypes exists with each being clinically distinct and most 
often associated with P. falciparum infection, though some cases have been associated 
with P. vivax and P. ovale [136]. An increased risk of severe response has been associated 
with specific risk factors including ethnicity both broadly, with Asian and White 
populations with a higher risk of severe response [139], and specifically, for example 
associations with the Dantu blood group antigen [140]. 
Example of severe subtypes include severe malarial anaemia (indicated by a significantly 
low haemoglobin concentration level, typically below 5 g/dl for under 12s [141]), 
hyperlactatemia (indicated by blood lactate levels above 5 mmol/L [141]), respiratory 
distress (which develops in approximately 40% of children with severe P. falciparum 
malaria [142]), and cerebral malaria (typically diagnosed via evaluation with the Blantyre 
coma scale which considers eye movement, motor responses, and verbal response score 
< 5 [141]). 
 
1.4.3 Genetics of human susceptibility 
Centuries of host-pathogen interactions between human hosts and their malaria parasites 
have had a significant impact on the human genome, particularly within Africa, leading 
the claim that the disease has been the largest selective force upon the human genome in 
recent history [12]. 
One study estimated that approximately 25% of disease variance for severe malaria is 
determined by human genetic factors [143]. Multiple variants account for this risk, though 
the majority are associated with classic examples such as HbS (sickle cell trait), alpha-
thalassemia, ABO blood type, Duffy negative status, and G6PD deficiencies [144,145]. 
A wealth of other variants of less significant impact, such as USP38, FREM3, 
glycophorins gypA/B/E, DDC, and ATP2B4 have also been identified as being associated 
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with severity of response though are, in sum, less protective than heterozygous carriage 
of HbS [146–150]. Indirect impacts of human genetics also exit, for example twin studies 
have suggested that a genetic component underpins the likeliness that different 
individuals are bitten by a mosquito, and therefore the probability of initial infection 
[151]. 
Several variants protective against malaria are also associated with a high risk of an 
alternative disease, predominantly forms of anaemia, highlighting complex patterns of 
evolutionary selection. The most well-known example of a genetic variant associated with 
protection against malaria is carrier status for sickle cell anaemia. Heterozygous carriage 
of the HbS sickle variant is associated with an almost 90% reduced risk of severe malaria, 
due to the reduced ability for Plasmodium parasites to infect the malformed sickle-shaped 
erythrocytes [152]. In contrast, homozygous carriage of the sickle variant of HBB instead 
leads to sickle cell anaemia, a disease in which half of patients die before they reach fifty 
[153]. 
Alpha-thalassemia and G6PD deficiency represents two other anaemia-associated forms 
of malarial-protective variants. Alpha-thalassemia is an impairment of proper 
haemoglobin production, where an individual has an irregular ratio of alpha, beta and 
gamma haemoglobin chains with an excess of inefficient beta tetramer and gamma chain 
oxygen carriers and is typically caused by deletions of or within HBA1 or HBA2 [154]. 
This disruption results in severe anaemia, alongside resilience to malarial infection, and 
is therefore selected against in non-malarial regions causing global alpha-thalassemia 
distribution to be highly correlated with malaria-endemic regions [155]. In contrast, 
G6PD deficiency is the underproduction of glucose-6-phosphate dehydrogenase (G6PD), 
an intracellular enzyme that catalyses NADPH production through reduction of NADP+ 
[156]. Deficiencies in G6PD production result in haemolysis whilst also providing a 
degree of resistance to uncomplicated P. falciparum malaria infection [157]. As with 
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sickle cell anaemia and alpha-thalassemia, selection for malaria protection over the 
resulting anaemia results in GP6D deficiency being distributed within malaria-endemic 
regions [158]. 
Other variants only convey protection to specific Plasmodium species, for example P. 
vivax and P. knowlesi utilise host surface antigens such as the Duffy antigen receptor 
(encoded by DARC) to enter human erythrocytes. Deletions of the Duffy antigen receptor 
therefore provide resistance to merozoite invasion [159], with this being reflected in the 
global distribution of the Duffy-negative trait to regions with high levels of P. vivax 
infection. 
Recent developments in high-throughput sequencing technologies have allowed the 
expansion from laboratory-based candidate gene studies to genome-wide discovery 
approaches. The utilisation of genome-wide association studies (GWASs) have led to the 
identification of several loci associated with the severity of human response to 
Plasmodium infection [145,150] with some being associated with specific subtypes, such 
as ADAMTS13 with cerebral malaria [160]. With greater data resolution, our 
understanding of human genetics in the context of malaria has grown more complex, with 
a significant number of SNPs only being found in association for specific populations 
[161]. The search for additional factors is therefore potentially hindered by a lack of 
African genomes for both primary variant discovery and improving existing reference 
panels with localised imputation, for example the 1000 Genomes Project only includes 
seven African populations of which two are based in the USA and Barbados [162]. It is 
also likely that human genetic factors with more subtle phenotypic impacts differ by 
geographical region due to inherently weaker selection, for example a variant associated 
with malaria protection in West Africa may be not be associated in East Africa. This 
biogeographical nature of some variants highlights the potential benefit of personalising 
treatment and control approaches to local populations, an incentive that would benefit 
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from strong, local health infrastructures. Further the use of other whole genome methods, 
and complementary protein, epigenetics, and other ‘omics approaches is likely to 
continue identifying novel inherent host factors relevant to malaria through which future 
treatments and control methods can be better informed. 
 
1.5 Methods utilised in exploring genomics 
1.5.1 High throughput sequencing 
‘Next generation’ high throughput sequencing approaches have facilitated the rapid 
growth of bioinformatic analysis since the turn of the century, having found utility for a 
wealth of applications across clinical and microbiological settings [163]. Milestone 
achievements include the sequencing of the human genome in the 2000s [164] and the 
emergence of novel methods such as large-scale genome-wide association studies [165]. 
High throughput sequencing technologies can be loosely classified into two forms based 
on the length of their raw outputs, known simply as ‘short read’ and ‘long read’ 
sequencing. 
Short read based sequencing methods include 454 pyrosequencing [166], Ion Torrent 
[167], and Illumina platforms [168], amongst others, and typically produce raw reads 
shorter than 1000 bp. These approaches generally involve fragmentation of the DNA 
molecule followed by sequencing of those short sections. The result is an abundance of 
short reads that either require aligning against a reference or de novo assembling for 
interpretation. Recent improvements have centred on cost effectiveness, with Illumina 
claiming its first ‘$1000 genome’ in 2015, with that cost being $200,000 in 2009 [169]. 
Long read based sequencing methods aim to sequence large sections of DNA, with the 
unofficial goal of sequencing entire chromosomes without assembly. These approaches 
tend to be newer and include single-molecule real-time sequencing (SMRT) from Pacific 
Biosciences, and Nanopore, as provided by Oxford Nanopore. These methods are better 
34 
 
 
suited towards the resolution of highly repetitive regions, which short read approaches 
have difficulty resolving [170], and reduce issues related to reference genomes with 
multiple regions of high similarity [171]. In theory, long read methods should also be able 
to better resolve complex structural variation events, for example a duplication would be 
present in the raw reads and not require inference from coverage or breakpoint-based 
analysis. Recent improvements have focused on enhancing accuracy, with Nanopore 
specifically having a high stochastic error rate [172]. 
 
1.5.2 Genomic variation in host-pathogen interactions 
Genomic variation underpins many heritable forms of antimalarial resistance for malaria 
parasites [173], and types of malaria susceptibly for infected humans [174]. These 
variants range from single base single nucleotide polymorphisms (SNPs) to large 
genomic regions mutated by structural variations such as deletions, duplications, 
insertions, and inversions [175]. Once identified, the specific variants present can be used 
to infer signals of genetic diversity, selection, and association within and between wider 
populations [176]. 
Given this range of genetic variants a range of methods for their detection has been 
developed. For example, SNPs and small insertions/deletions (indels) have classically 
been detected using lab-based methods such as microarrays [177], or with in silico read-
alignment based methods such as variant calling [178]. Typically, for an in silico 
approach, short or long reads are aligned to a reference genome with software such as 
bwa or minimap2 with variants relative to that reference being identified with a tool such 
as mpileup [179–181]. 
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1.5.3 Identifying signals of selection 
Once detected, SNPs can form the basis of methods to identify signals of selection either 
as independent features or grouped into inherited sets known as haplotypes. Methods for 
determining selection therefore range from simple measures of variant frequency, either 
over time or between populations, to more complex measures of locus conservation. 
Fixation indexes (FST) are a group of methods that identify differences in population 
frequencies, they include Nei’s, Wright’s, and Weir and Cockerham’s methods with some 
optimised for specific uses such as unequal sample sizes [182–184]. All consider relative 
variant frequencies between two or more populations with larger values (further from 0, 
closer to 1) indicating that the frequency of a variant in one or more populations is 
significantly different in the other populations [182–184]. These slight distinctions can 
make comparison between different forms complex in their minutia, despite them all 
being referred to as ‘FST’.  
Simple haplotype-based methods include Tajima’s D, in which variation within pre-
defined regions is compared between two or more samples [185]. This method effectively 
considers the difference between the true average number and the expected number of 
polymorphisms between the considered sample pairs. More specifically, Tajima’s D 
compares the differences between two estimates of genetic diversity in a population: 
Tajima’s estimator (dT), the sum of pairwise-differences between haplotypes over the 
number of pairwise comparisons (number of samples choose two), and Watterson’s 
estimator (dW), the number of segregating sites over the (number of samples - 1)th 
harmonic number. Tajima’s D for a sequence is therefore (dT – dW) over the standard 
deviation of (dT – dW) for all sequences. Positive Tajima’s D values indicate an 
abundance of rare variants and therefore suggesting recent selection, whilst negative 
values indicate a lack of rare variants suggesting balancing selection [185]. This metric 
can also be applied on a ‘per-gene’ basis, rather than for fixed sized windows, meaning 
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that biological validity may be gained at the cost of more complex comparisons due to 
different sized SNP sets. Specific limitations of this approach include the requirement for 
biallelic sequence differences, difficulties in applying the method to complexly structured 
populations, and biases introduced for populations growing at an exponential rate. 
More complex and newer statistical approaches will consider conservation of haplotypes 
around specific loci. Extended haplotype homozygosity (EHH) based methods, such as 
integrated haplotype scores (iHS) and cross population extended haplotype homozygosity 
(XP-EHH), are based on the comparison of conserved haplotype length around specific 
SNPs for different core alleles (iHS) or different populations (XP-EHH) [186,187]. 
Similar methods, such as HaploPS, instead identify selection as abnormally long 
haplotypes for a SNP compared to haplotypes of a similar frequency [188]. 
EHH is defined as “the probability that two randomly chosen chromosomes carrying the 
core haplotype of interest are identical by descent (as assayed by homozygosity at all 
SNPS) for the entire interval from the core region to the point x” [189]. iHS then utilises 
those base EHH scores and calculates an integrated score under the EHH curve for both 
ancestral (reference) and derived (alternative) core alleles (iHHA and iHHD respectively). 
iHS is then calculated as the ratio of iHHA over iHHD and values standardised relative to 
all other iHS scores for a specific genome of interest [186]. XP-EHH takes a similar 
approach to consider relative differences in haplotype conservative between two 
population, this is calculated as the natural log of the integrated EHH for a SNP of interest 
in population A over the equivalent iHH for population B (with the equivalent 
standardisation) [187]. 
EHH-based approaches therefore share some specific limitations, for example 
appropriately phased haplotypes are required and errors introduced during phasing may 
therefore be inherited. Further these approaches rely upon there being a sufficient density 
of biallelic SNPs across the genome and will therefore exclude regions with notably high 
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or low levels of variation, though this is similarly true for other methods that utilise SNP 
frequencies or associations. This required level of variation also means that EHH methods 
are generally geared towards the detection of more recent selection events, which may be 
viewed as a feature rather than a bug. Conversely, genomic regions under consistently 
high levels of selection, and therefore displaying a low number of SNPs in the population, 
are generally unsuitable for EHH-based approaches. Strong purifying signals of selection 
present within the full population may therefore be overlooked, though these may be 
identified with cross-population approaches, such as XP-EHH. 
Notable positives to an EHH approach include the ability to identify the specific allele or 
population under selection. Further dissection of the EHH curves can also identify skews 
within that selection, whether up or downstream of the core SNP, allowing the inference 
of specific sub-regions under strong conservation. EHH-based approaches also 
incorporate linkage disequilibrium, rather than treating SNPs as purely independent 
events, and therefore more accurately represent the molecular mechanisms underpinning 
signatures of selection. Together these factors ensure that EHH-based methods are 
suitable for the identification of recent selection events relating to relatively frequent 
variants, such as those associated with emerging drug resistance. Context is also 
important for selection methods such as these, as selection signals are often normalised 
over a selection of target loci. For EHH-based methods this can mean that the exclusion 
of certain regions or SNPs can skew normalisation if it is not appropriately controlled for. 
 
1.5.4 Identifying structural variation 
Traditionally structural variants have been identified through lab-based approaches such 
as PCR and DNA probes, which benefit from being able to directly examine putative 
variants but are limited to slower analysis of small sample sets [190]. In contrast 
computational approaches benefit from faster, higher-throughput analysis, allowing 
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specific regions to be highlighted for follow up investigation in the lab. Most recently 
developed in silico approaches tend to utilise read-based inputs to examine paired read 
realignment [191,192] or aligned read depth [193,194]. Read depth approaches, such as 
CNVNator or Control-FREEC, involve mapping reads against a reference genome and 
identifying duplications and deletions as deviations from an expected read depth 
[193,194]. Deletions will appear as a genetic region in which nearly zero reads map to 
the reference, whereas duplications are regions where read depth is double or more of the 
expected depth [193,194]. This approach requires controlling for regions of poor mapping 
and accounting for significant GC biases, but tends to be relatively successful at 
identifying strong signals of significant length. An appropriately sized window is also 
required, to account for per-base variation, which can limit the size of structural variants 
that can be identified. Typically, this bottom limit has been around 500 bp leading to a 
low detection of smaller CNVs. When considering other forms of structural variation, 
such as inversions and insertions, read depth-based methods can be limited as these forms 
of structural variation tend not to impact read depth. 
Instead, read realignment approaches such as DELLY or LUMPY are considered. These 
realign each read to the reference genome to determine if specific reads are split across a 
probable breakpoint, a point where a structural variant begins or ends, or to identify 
anomalous read pairing. For example, an inversion can be detected when a significant 
number of reads align in reverse to their paired read, or a duplication might be identified 
by a read aligning in the same direction but the wrong side of its paired read [191,192]. 
Many of the limitations of read alignment-based methods, such as the need for enough 
high-quality reads across the whole genome of interest, are shared with alignment-based 
genome assembly and read depth SV detection approaches but may present differently. 
For example, poor quality reads for a specific region may lead to a false positive deletion 
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through a depth-based method but would require significantly poorly quality reads than 
for a similar detection in a realignment-based method. 
Consideration of the phasing of structural variants may alleviate some of these issues, for 
example predicted heterozygous genotypes for a haploid organism may suggest 
contamination, poor quality sequencing or more complex structural variation worthy of 
further investigation. Typically, methods will utilise specific parameters regarding read 
quality thresholds, or provide metrics relating to the number of paired or split reads that 
support the existence of a specific structural variant. These may then be incorporated as 
a secondary quality filter, post-detection. 
Short read based approaches are those most often utilised for structural variant detection 
given their established presence within bioinformatics, but these can be limited by 
alignment bias against subtelomeric regions, cryptic alignment due to repetitive regions 
(such as var, stevor, or rifin genes), and biases involved in GC skew [195]. Long read 
approaches can resolve some of the issues associated with poor alignment but structural 
variants detection methods for these are in early development. These newer sequencing 
technologies also bring new issues such the stochastic errors seen with Oxford Nanopore 
[172] and low read depth removing the ability to identify significant concordance between 
reads. Ideally both long and short reads should be considered alongside both read depth 
and realignment approaches. 
 
1.6 Project Outline 
This thesis examines the global genomics of host-pathogen interactions in malaria for 
populations of both the major causal parasite, P. falciparum, and humans in malaria-
endemic countries, primarily Tanzania. For each species I began by considering the role 
of SNPs and signals of selection, before extending to large scale explorations of structural 
variation. This large-scale exploration was facilitated by the development of an analysis 
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and visualisation tool, SV-Pop, and a pipeline for the detection of inversions in long read 
assemblies. 
 
Beginning with those chapters concerning the P. falciparum parasite, Chapter Two 
considers the impact of sustained SP use on the Plasmodium population within Malawi 
relative to its neighbouring countries, and the wider global population. Primarily this 
meant characterising SNPs known to be associated with anti-malarial resistance, before 
extending to the identification of novel selection signals and structural variants. Selection 
signals were identified in several loci including those with known to be associated with 
SP resistance. Investigation of chloroquine resistance variants revealed their near absence 
in the Malawian parasite population, demonstrating the ability for this resistance to leave 
a population when chloroquine use is restricted. In contrast variants associated with SP 
resistance were present at high frequency, with this being supported by corresponding 
selection signals. Structural variation was also considered with one striking 436 bp 
duplication being found at near fixation in the population immediately upstream of gch1, 
a gene for which whole gene duplications have been previously associated with SP 
resistance [75]. 
 Following discovery of this duplication in Malawi and given the previously 
unexplored biogeography of structural variation in P. falciparum, Chapter Three 
considers my utilisation of over 3,000 samples to explore the global variation of copy 
number variants in the P. falciparum population. This added global resolution to 
previously identified duplications of mdr1, enhanced our understanding of the Central 
and East African distribution of the 436 bp gch1 promoter duplication identified in 
Chapter Two, and identified novel duplications of crt unique to West Africa which may 
be associated with the dual carriage of chloroquine resistant and susceptible alleles. 
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Population specific variants were also identified in genes such as rh2b, rhopH2, and the 
ring-infected erythrocyte surface antigen PF3D7_0102200. 
 The large-scale approach to structural variant exploration described in Chapter 
Three highlighted intricacies in short read-based methods which undermined successful 
detection of inversions. To resolve this, Chapter Four describes the development of a 
method for inversion detection from long read assemblies, which better resolve regions 
that short read approaches find difficult. This method was then applied to a selection of 
lab cultured and field isolated samples from around the globe. Multiple putative 
inversions were identified in several highly variable var, rifin, and stevor genes, historical 
tandem inversions present for RH2a/b and elongation factors 1-alpha, and a novel 
sandwich inversion of pi4k identified in GB4, a lab adapted strain of P. falciparum. 
 
The human-focused analyses initially considered the severity of malaria response through 
a case-control genome-wide association study before extending towards an investigation 
of genomic structural variation within a similar Tanzanian population, with a focus on 
genes associated with P. falciparum interaction. Tanzania is a highly malaria endemic 
region in which the local population experience a range of symptomatic responses to P. 
falciparum infection including a range of severe malarial subtypes. Chapter Five 
describes work to identify novel genetic variants associated with a higher or lower risk of 
disease severity. This required application of a mixed model genome-wide case-control 
association study, with that core analysis being complemented by an examination of 
signals of selection genome-wide and candidate region exploration of structural variation. 
Here novel SNPs associated with severe malaria response, including two interleukin 
receptors (IL-23R and IL-12RBR2), were identified, alongside signals of selection for loci 
such as SYNJ2BP and GCLC. 
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 Chapter Six sheds light on the abundance of structural variation within the 
Tanzanian human genome by up-scaling the structural variation work from Chapter Five 
to a whole genome context. Here I identified just short of 200,000 putative variants in 
156 parents, of which 6,932 specific forms were frequent (>5%) and a mean of 16.7% per 
parent were inherited without mutation to their child (n=78). Gene ontology analysis 
highlighted enrichment for cell adhesion, drug binding, and intracellular transport 
functions. Amongst the wide array of variants some, such as a 4,136 bp deletion of 
SEC22B (98.7%) and a 220 bp deletion in BET1L (98.7%), were present at near-fixation. 
Focus was also applied to candidate genes associated with known roles in blood antigen 
systems and the risk of severe malaria. This led to the identification of novel SVs in 
A4GALT, ATP2B4, and ABCG2, with the latter potentially being a novel form of the 
typically highly rare Jr(a-) blood phenotype. 
 
Chapter Seven describes SV-Pop, a package I developed in Python and R for the high-
throughput, multi-population analysis and visualisation of structural variation. Its use was 
demonstrated in Chapters Three and Six in which it was used for variant filtering and 
analysis, as well as visualisation of the larger datasets. Given the species agnostic nature 
of this tool, future applications could facilitate exploration of global structural variation 
in other malaria species, such as P. vivax, or mosquito populations. 
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Chapter 2: 
Characterising the impact of sustained 
sulfadoxine/pyrimethamine use upon the Plasmodium falciparum 
population in Malawi 
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Additional Figure 1: Clustering through Principal Components Analysis of the 
combined dataset. Analysis is based on a pairwise Manhattan distance SNP matrix for 
all samples; (A) East Africa; (B) Africa; (C,D) Global. Colours indicate countries with 
point styles indicating continents. West Africa (n=430): Burkina Faso (BUF, 39), 
Gambia (GAM, 55), Ghana (GHA, 202), Guinea (GUI, 95), Mali (MAI, 35), Nigeria 
(NIG, 4); Central and East Africa (n=253): Dem. Rep. of Congo (DRC, 56), Kenya 
(KEN, 15), Malawi (MAW, 220), Tanzania (TAN, 18); South and South-East Asia 
(n=1187): Bangladesh (BAN, 54), Cambodia (CAM, 526), Laos (LAO, 104), Myanmar 
(MYA, 95), Papua New Guinea (PNG, 11), Thailand (THA, 210), Vietnam (VIE, 187); 
South America (n=21); Colombia (COL, 14), Peru (PER, 7). 
  
71 
 
 
Additional Figure 2: XP-EHH around gch1 comparing the Malawi population with 
those from the DRC, Ghana and Guinea. Negative values indicate relative fixation in 
Malawi, whilst positive values indicate relative fixation in the non-Malawian 
population. Green indicates gch1 whilst the immediate grey bars indicate the same 
neighbouring genes as in Figure 2. In addition, the two upstream genes Pf3D7_1223400 
and Pf3D7_1223500 with the most significant XP-EHH are highlighted in grey. Red 
lines indicate our significance threshold of absolute XP-EHH scores greater than 4. 
  
72 
 
 
Additional Figure 3: XP-EHH selection around gch1 between duplication-positive 
and duplication-negative DRC, Ghana and Guinea populations. Negative values 
indicate relative fixation in the duplication-positive population, whilst positive values 
indicate relative fixation in the duplication-negative population. Green indicates gch1 
whilst the immediate grey bars indicate the same neighbouring genes as in Figure 2. In 
addition, the two upstream genes Pf3D7_1223400 and Pf3D7_1223500 with the most 
significant XP-EHH are highlighted in grey. Red lines indicate our significance 
threshold of absolute XP-EHH scores greater than 4. 
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Additional Figure 4: Coverage for the gch1 region in five reference strains. Whilst 
the previously identified gch1 duplication is present within 3D7 (ERS009999), 7G8 
(ERS016318), DD2 (ERS010540) and GB4 (ERS016319) and confirmed absent in HB3 
(ERS010539), no reference sample was shown to contain the novel promoter 
duplication. Green indicates gch1, blue indicates the region for the most frequent 
promoter duplication, and grey indicates neighbouring genes. Coverage is scaled against 
the median coverage (indicated by the dashed red line) for chromosome 12 and 
calculated for 100bp windows, with an offset of 25bp. 
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Additional Table 1: Pairwise differences between Malawi seasonal sub-populations. 
 
Chikwawa 
2011 (Wet) 
(n=22) 
Chikwawa 
2011 (Dry) 
(n=64) 
Chikwawa 
2012 (Wet) 
(n=34) 
Chikwawa 
2012 (Dry) 
(n=57) 
Zomba 
2012 (Wet) 
(n=31) 
Chikwawa 
2011 (Wet) 
(n=22) 
9458 
(7607 -10400) 
9434 
(6130-11020) 
9458 
(6229-10660) 
9538 
(5951-10640) 
9522 
(6131-
10740) 
Chikwawa 
2011 (Dry) 
(n=64) 
0.01 
(0.00-0.19) 
9381 
(4560 - 11190) 
9395 
(4484-11140) 
9474 
(4270-11100) 
9442 
(4681-
11140) 
Chikwawa 
2012 (Wet) 
(n=34) 
0.01 
(0.00-0.20) 
0.01 
0.00-0.12 
9396 
(900-10710) 
9485 
(4440-10810) 
9438 
(4724-
10770) 
Chikwawa 
2012 (Dry) 
(n=57) 
0.01 
(0.00-0.19) 
0.01 
(0.00-0.12) 
0.01 
(0.00-0.12) 
9557 
(4758 - 
10700) 
9536 
(4651-
10880) 
Zomba 
2012 (Wet) 
(n=31) 
0.01 
(0.00-0.22) 
0.01 
(0.00-0.19) 
0.01 
(0.00-0.15) 
0.01 
(0.00-0.14) 
9448 
(522 - 
10680) 
 
Upper and diagonal values indicate median (range) number of SNP differences between individuals.  Lower 
values indicate median (range) FST values across SNPs for each sub-population pair. 
  
75 
 
 
Additional Table 2: Top FST values for pairwise Malawi sub-population comparisons. 
Locus Gene Max Fst Other Fst 
PF3D7_1038400 Gametocyte specific protein 0.220 0.001 – 0.202 
PF3D7_1008500 Conserved unknown 0.199 0.000 – 0.187 
PF3D7_0420000 Putative zinc finger 0.198 0.001 – 0.152 
8:1309330 Intergenic 0.191 0.001 – 0.097 
7:1345508 Intergenic 0.188 0.000 – 0.128 
PF3D7_0707300 Rhoptry-associated membrane antigen 0.180 0.002 – 0.118 
PF3D7_1326400 Putative translation initiation factor eIF-2B 0.178 0.000 – 0.126 
4:1061702 Intergenic 0.178 0.000 – 0.172 
PF3D7_0710000 Conserved unknown 0.174 0.000 – 0.050 
PF3D7_0525000 Putative zinc finger 0.173 0.009 – 0.118 
PF3D7_1446500 Conserved unknown 0.173 0.001 – 0.134 
PF3D7_1477600 SURFIN 14.1 0.172 0.000 – 0.117 
4:545378 Intergenic 0.170 0.001 – 0.071 
PF3D7_0708400 Heat Shock Protein 90 0.166 0.001 – 0.142 
PF3D7_0709300 Putative Cg2 protein 0.165 0.005 – 0.084 
6:824765 Intergenic 0.164 0.001 – 0.132 
8:698268 Intergenic 0.162 0.001 – 0.083 
PF3D7_1200700 Acyl-CoA Synthetase 0.158 0.000 – 0.121 
PF3D7_1135600 Putative condensin-2 complex subunit D3 0.158 0.000 – 0.053 
9:91336 Intergenic 0.157 0.000 – 0.144 
PF3D7_0905400 High molecular weight rhoptry protein 3 0.157 0.002 – 0.078 
PF3D7_0412400 PfEMP1 0.157 0.000 – 0.076 
PF3D7_0310200 Putative phd finger protein 0.156 0.001 – 0.132 
PF3D7_1325400 Conserved unknown 0.152 0.001 – 0.105 
PF3D7_0629300 Putative phospholipase 0.151 0.001 – 0.128 
 
Threshold of greater than 0.15. 
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Additional Table 3: Allele frequencies for Sulfadoxine-Pyrimethamine resistance 
mutations within Malawi across all seasons. 
Genetic variant 
Chikwawa 
2011 Wet 
Chikwawa 
2011 Dry 
Chikwawa 
2012 Wet 
Chikwawa 
2012 Dry 
Zomba 
2012 Wet 
Combined 
population 
Sample Size 22 64 38 57 27 220 
dhps       
S436A 0 0 0.026 0 0 0.005 
A437G 1 1 0.987 1 1 0.998 
K540E 1 0.992 0.987 1 1 0.995 
dhfr*       
N51I 1 1 1 0.983 1 0.991 
C59R 0.955 0.984 1 0.991 1 0.991 
S108N 1 1 1 1 1 1 
Triple mutant** 0.955 0.984 1 0.965 1 0.977 
gch1***       
Promoter 
duplication 
1 0.938 0.974 0.965 1 0.968 
 
*I164L (quadruple mutation) is not present; ** dhfr N51I, C59R & S108N haplotype; *** Whole gene 
duplication of gch1 is absent. 
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Additional Table 4: Top hits for Malawi-only positive selection (iHS) analysis. 
Gene ID Position iHS Gene 
PF3D7_0208600 355154 -4.376 RRF1 
PF3D7_0417400 758290, 758269 -4.678, -4.448 Conserved unknown (near1 dhfr) 
PF3D7_0505100 226777 -4.502 TRS85 
PF3D7_0511400 481921 4.516 Conserved unknown 
PF3D7_0808200 417751 4.686 Plasmepsin X 
PF3D7_0809600 484954, 490762 4.906, 3.962 Putative petidase family C50 (near2 dhps) 
PF3D7_0814600 703454 4.519 Conserved unknown 
PF3D7_0826000 1111727 5.272 Conserved unknown 
PF3D7_1002200 1115470, 1115617 -5.604, -5.396 PArt/TrpA-3 
PF3D7_1133400 1294082, 1294982 5.129, 5.017 ama1 
PF3D7_1223400 943339 -4.947 Phospholipid-transporting ATPase (near3 gch1) 
PF3D7_1335900 1466252, 1466264 5.366, 5.209 trap 
PF3D7_1352900 2114996 6.066 Exported unknown 
 
Positive scores indicate selection for the alternative core allele, whilst negative scores indicate 
selection for the reference core allele. All hits are above a threshold of 4 ( |iHS|>4 ). 
  
                                                 
1 Within 10 kbp 
2 Within 50 kbp 
3 Within 5 kbp 
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Additional Table 5: Top Tajima’s D values for the combined Malawi population. 
Gene ID Gene Tajima’s D 
PF3D7_0710200 Conserved unknown 3.224 
PF3D7_0830800 surf8.2 3.196 
PF3D7_1133400 ama1 2.916 
PF3D7_0424400 surf4.2 1.605 
PF3D7_1335900 trap 1.503 
PF3D7_0113800 DBL-containing protein 1.475 
PF3D7_1475900 Conserved unknown 1.205 
PF3D7_1004800 Putative ADP/ATP carrier protein 1.080 
PF3D7_1035700 Duffy binding-like merozoite surface protein 0.970 
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Additional Table 6: Drug resistance candidate mutation frequencies  
Gene/SNP 
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Sample Size 220 18 15 56 39 55 202 95 35 4 54 527 95 11 104 210 187 14 7 
 dhps                    
S436A 0.005 0.056 0.067 0.107 0.538 0.100 0.609 0.458 0.657 0.250 0.509 0.342 0.332 0 0.212 0.250 0.366 0 0 
A437G 0.998 0.944 0.833 0.902 0.615 0.764 0.705 0.705 0.257 1.000 0.84 0.895 1.000 0.227 0.572 1.000 0.799 0.071 0.714 
K540E 0.995 0.944 0.833 0.062 0 0 0.010 0.042 0 0 0.778 0.341 0.9 0.136 0.178 0.907 0.348 0 0.571 
 dhfr                    
N51I 0.991 0.944 0.867 0.982 0.359 0.918 0.592 0.821 0.486 1.000 0.471 0.925 0.901 0 0.644 0.938 0.963 0.214 0.714 
C59R 0.991 1.000 0.867 0.821 0.423 0.845 0.757 0.879 0.486 1.000 0.972 0.996 1.000 0.955 0.976 1.000 1.000 0 0 
S108N 1.000 1.000 1.000 1.000 0.397 0.936 0.817 0.879 0.471 1.000 1.000 1.000 1.000 1.000 0.976 1.000 1.000 0.929 1.000 
I164L 0 0 0.052 0 0 0 0 0 0 0 0.382 0.432 0.861 0 0.008 0.798 0.231 0 0.200 
N51I+C59R 0.977 0.944 0.733 0.750 0.179 0.836 0.490 0.789 0.400 1.000 0.370 0.918 0.905 0 0.606 0.933 0.952 0 0 
N51I+S108N 0.991 0.944 0.867 0.982 0.154 0.909 0.525 0.779 0.371 1.000 0.389 0.916 0.905 0 0.606 0.933 0.947 0.214 0.714 
C59R+S108N 0.986 1.000 0.867 0.768 0.205 0.836 0.713 0.853 0.371 1.000 0.944 0.996 1.000 0.909 0.971 1.000 0.995 0 0 
Triple Mutant* 0.977 0.944 0.733 0.750 0.154 0.836 0.490 0.779 0.371 1.000 0.370 0.916 0.905 0 0.606 0.933 0.947 0 0 
Quadruple 
Mutant** 
0 0 0 0 0 0 0 0 0 0 0.167 0.422 0.811 0 0.010 0.752 0.203 0 0 
 crt                    
K76T 0 0.722 0.200 0.661 0.205 0.727 0.223 0.674 0.514 1.000 0.889 0.973 0.989 0.909 0.885 0.981 0.925 1.000 1.000 
Q271E 0 0.722 0.200 0.643 0.205 0.727 0.233 0.663 0.657 1.000 0.907 0.941 0.979 0 0.885 0.986 0.914 0 0 
N326S 0 0 0 0 0 0.018 0 0 0 0 0.241 0.647 0.989 0 0.115 0.952 0.358 0 0 
I356T 0 0 0 0.196 0.026 0.636 0.015 0.126 0.229 0.250 0.833 0.672 0.989 0 0.115 0.990 0.380 0 0 
 kelch13                    
K189T 0.091 0.056 0.067 0.196 0.615 0.545 0.530 0.411 0.400 0.500 0.130 0 0.011 0 0 0 0 0.857 0.429 
K189N 0.005 0 0 0 0.026 0.091 0.020 0 0.029 0 0 0 0 0 0 0 0 0 0 
Y493H 0 0 0 0 0 0 0 0 0 0 0 0.087 0 0 0 0 0.021 0 0 
C580Y 0 0 0 0 0 0 0 0 0 0 0 0.387 0.105 0 0 0.138 0.059 0 0 
 gch1                    
No duplication 0.032 1 1 0.534 1 0.909 0.658 0.547 0.971 1 0.852 0.954 0.926 1 0.990 0.852 0.893 1 1 
Promoter 
duplication 
0.968 0 0 0.446 0 0.091 0.292 0.453 0.011 0 0.037 0.002 0 0 0 0.010 0 0 0 
Whole gene 
duplication 
0 0 0 0.020 0 0 0.050 0 0 0 0.111 0.044 0.074 0 0.010 0.138 0.107 0 0 
*dhfr N51I, C59R & S108N haplotype. ** dhfr N51I, C59R, S108N & I164L haplotype; DRC Democratic 
Republic of Congo 
 
  
80 
 
 
Additional Table 7: Top hits for Malawi pairwise positive selection (XP-EHH) analysis. 
Gene ID Populations XP-EHH** Gene 
PF3D7_0212500 DRC 6.511 Conserved unknown 
PF3D7_0215300 DRC, Ghana, Guinea -6.087, -6.912, -6.872 acs8; Acyl-CoA synthetase 
PF3D7_0307900 DRC -6.866 Conserved unknown 
PF3D7_0321800 Ghana 6.802 WD repeat-containing protein 
PF3D7_0416900 Mali -6.257 Conserved unknown (near dhfr) 
PF3D7_0417400 Colombia, Ghana -6.184, -6.323 Conserved unknown (near dhfr) 
PF3D7_0513200 Laos 6.037 Conserved unknown 
PF3D7_0525100 Ghana, Guinea -6.337, -6.514 acs10; Acyl-CoA synthetase 
PF3D7_0526600 Laos, Mali 7.018, -6.181 Conserved unknown 
PF3D7_0529000 
Bangladesh, Laos, 
Myanmar 
7.162, 6.947, 6.245 Conserved unknown 
PF3D7_0620400 
DRC, West Africa, 
Myanmar 
5.981, 11.079, 6.125 Msp10 
PF3D7_0629700 DRC 7.241 Set1 
PF3D7_0709100 
Bangladesh, DRC, Gambia, 
Southeast Asia 
7.529, 9.330, 7.759, 8.663  Cg1 protein (near crt) 
PF3D7_0709200 
Cambodia, Myanmar, 
Thailand 
6.327, 6.259, 6.095 GLP3 (Cg6 protein) (near crt) 
PF3D7_0709300 
Cambodia, DRC, Thailand, 
Vietnam 
6.759, 8.073, 7.229, 6.470 cg2 (near crt) 
PF3D7_0709600 DRC, Gambia 8.498, 6.520 pop1 
PF3D7_0710000 Peru 6.019 Conserved unknown 
PF3D7_0810200 Gambia -6.132 ABCK1 
PF3D7_0810600 Guinea -6.477 
ATP-dependent RNA helicase 
DBP1 
PF3D7_0810800 
Colombia, Guinea, Laos, 
Vietnam 
-6.257, -6.532, -6.257, -6.125 dhps 
PF3D7_0810900 Colombia -6.257 Conserved unknown (near dhps) 
PF3D7_0926500 Bangladesh -6.266 Conserved unknown 
PF3D7_1223400 DRC, West Africa, Kenya -10.114, -9.217,-7.852 near gch1 
PF3D7_1223500 
DRC, Gambia, Ghana, 
Guinea, Kenya 
-9.998, -6.640, -6.434, -7.130, -
6.431 
near gch1 
PF3D7_1218300 Ghana 6.294 ap2mu 
PF3D7_1227500 DRC -6.231 cyc2 
PF3D7_1335800 DRC 6.679 Conserved unknown 
PF3D7_1352900 Cambodia, Colombia 6.357, 6.498 Exported unknown, fam-f protein 
PF3D7_1324300 Gambia, Ghana, Guinea 6.295, 6.722, 7.758 Conserved unknown membrane 
PF3D7_1335900 
Colombia, DRC, Mali, 
Peru, Tanzania, Vietnam 
6.682, 6.178, -6.171, 6.662, 
6.088, 8.256 
trap 
PF3D7_1421100 West Africa -9.650 Conserved unknown 
Positive (negative) scores indicate relative selection in the non-Malawi (Malawi) population. Bold indicates 
genes with known associations with drug resistance. DRC Democratic Republic of Congo. 
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Abstract 
The evolution of genetic mechanisms for host immune evasion and anti-malarial resistance has 
enabled the Plasmodium falciparum malaria parasite to inflict high morbidity and mortality on 
human populations. Most studies of P. falciparum genetic diversity have focused on single-
nucleotide polymorphisms (SNPs), enabling the identification of drug resistance-associated loci 
such as the chloroquine related crt and sulfadoxine-pyrimethamine related dhfr. Whilst larger 
structural variants are known to impact adaptation, for example, mdr1 duplications with anti-
malarial resistance, no large-scale, genome-wide study on clinical isolates has been undertaken 
using whole genome sequencing data. By applying a structural variant detection pipeline across 
whole genome sequence data from 3,110 clinical isolates in 21 malaria-endemic countries, we 
identified >70,000 specific deletions and >600 duplications. The majority of structural variants 
are rare (48.5% of deletions and 94.7% of duplications are found in single isolates) with 2.4% of 
deletions and 0.2% of duplications found in >5% of global samples. A subset of variants was 
present at high frequency in drug-resistance related genes including mdr1, the gch1 promoter 
region, and a putative novel duplication of crt. Regional-specific variants were identified and a 
companion visualisation tool has been developed to assist web-based investigation of these 
polymorphisms by the wider scientific community. 
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Introduction 
Plasmodium falciparum malaria imposes a heavy morbidity and mortality burden, with an 
estimated 216 million new cases and 446,000 deaths in 2016 alone, with ~90% of the burden in 
sub-Saharan Africa1. An understanding of the genomic diversity of P. falciparum parasites could 
provide insights into novel phenotypes that impact responses to antimalarials and other control 
measures, as well as host-pathogen interactions. Single nucleotide polymorphism (SNP) based 
analyses have revealed insights into drug resistance, molecular barcodes for continental origin2, 
transmission dynamics3, multiplicity of infection4 and regions under selective pressure related to 
immunological and anti-malarial treatment pressure5. In comparison, investigations of structural 
variants (SVs), such as insertions, deletions and duplications, have been sparse. This is despite 
SVs making an important contribution to genomic diversity and comprising many nucleotides of 
heterogeneity. In particular, copy number variants (CNVs; large indels and duplications) are 
thought to be widespread in the P. falciparum genome6 and more abundant than SNPs7. 
 
Malaria parasites are exposed to strong selection from the human immune response and treatment 
with antimalarial drugs. Subsequently, CNVs have often been found in association with specific 
P. falciparum phenotypes, such as drug resistance. Duplications of mdr1 have been shown to 
underlie a multi-drug resistance phenotype, with these variants now present at high population 
frequencies in Southeast Asia8, with copy number altering parasite response to multiple anti-
malarial drugs9. Recently, we identified a novel promoter duplication for gch1 at near-fixation in 
a Malawi population5, which is distinct from the whole gene duplication observed in Southeast 
Asia known to contribute to sulfadoxine-pyrimethamine (SP) resistance. In general, such regional 
genetic variation may arise from differences in drug regimens, mosquito vectors, and host 
immunity, but is poorly understood. 
 
Given their importance, a genome-wide structural variant map for P. falciparum with country and 
regional resolution should provide insights with which to better understand the impacts of 
treatment regimes, assess changes in parasite diversity, and ultimately inform the roll-out of anti-
malarial drugs and other control initiatives. The advent of microarray technologies, such as 
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genomic hybridisation arrays (CGH), has improved methods for detecting and confirming known 
SVs10,11. However, studies of this type have typically featured modest sample sizes and focused 
on the exome of lab-adapted isolates. The largest array-based study in P. falciparum clinical 
samples (n=122) identified 134 high-confidence CNVs across the parasite exome, established 
they were more common in South American than African or Southeast Asian populations, and 
identified several loci including mdr1, rh2b, and histidine-rich proteins II and III to be under 
positive selection11. Recently whole genome sequencing platforms, which produce a greater depth 
of short or long reads, have been used to detect SVs in P. falciparum strains7,12, and have 
potentially finer resolution than array-based approaches. Coupled with bioinformatic advances in 
detection algorithms, there is now capacity to accurately characterise a broader range of SV types. 
For example, extremes in coverage can identify duplications and deletions, split sequences and 
alternative de novo assembly-based approaches can detect a number of other types, including 
inversions and large insertions and deletions13. 
 
By analysing whole genome sequencing data from 3,110 clinical isolates and focusing on robust 
genomic regions (82.6%) of the AT-rich P. falciparum genome, we present the first 
comprehensive genomic map of SVs within the global P. falciparum population, with a particular 
focus on CNVs. We identify a total of 70,257 deletions (mean 403 per sample, median size 26 
bp) and 601 duplications (mean 0.39 per sample, median size 1,478 bp), contrasting with an 
average of 24,495 SNPs and 33,479 small indels (<15 bp) per sample. Several variants were found 
to be geographically specific and highlight novel structural variants with roles in antigenic 
variation, drug resistance, and host-pathogen interactions. PacBio sequencing data of P. 
falciparum strains was used to calibrate our bioinformatic pipeline and confirm specific 
candidates.  
 
Results 
Distribution of variant type, size and location 
The 3,110 samples represented 21 countries across Africa (Central, East, West), Asia (South, 
Southeast) and South America (Supplementary Table 1), and all displayed little evidence of 
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multiplicity of infection and non-anomalous coverage (see Methods). Using a bioinformatics 
pipeline based upon DELLY13, we identified more than 1 million putative variants relative to the 
3D7 reference genome, which after filtering (see Methods) was reduced to a total of 70,858 high 
quality variants (70,257 deletions: mean 402.88 per sample, median size 26 bp; 601 duplications: 
mean 0.39 per sample, median 1,478 bp). Of these, only 1,251 high quality specific large deletions 
(>500 bp; mean 1.39 per sample, median size 670 bp) and 385 duplications (>500 bp; mean 0.13 
per sample, median size 1,478 bp) were detected (Figure 1). The majority of the duplications 
(94.7%) and half the deletions (34,065 deletions; 48.6%) were unique to single isolates (total: 
34,634; 34,065 deletions and 569 duplications). Both deletions and duplications tend to occur 
within intergenic regions (intergenic/genic ratio: deletions 1.42, duplications 2.15). A (1 kbp) 
window-based analysis was used to identify regions with overlapping but distinct SVs. For 
deletions, 24,947 (of 27,388) windows (78.1% genic) were represented, compared to 2,441 
windows (80.4% genic) for duplications. 
 
Frequently occurring specific variants 
Previous work has shown that SVs present in a relatively high frequency of the global population 
are consistent with evidence of phenotypic selection11, and therefore we investigated variants 
identified in at least 5% of the global population (n=3,110). In total we identify 1,676 frequent 
variants of which only one is a duplication, this being the previously identified 436 bp gch1 
promoter region duplication5. Of all frequent variants, 723 (43.1%) are genic and the median 
length is 27 bp (Supplementary Table 2). Only five variants are greater than 500 bp in length, 
including four intergenic deletions (size range: 605 to 1,023 bp), and one 553 bp deletion in liver 
stage antigen 3 (PF3D7_0220000). Interestingly the 553 bp deletion in PF3D7_0220000 is 
present primarily in Southeast Asia, particularly Thailand (14.6%), Laos (11.5%), and Myanmar 
(11.2%) (Global 5.5%; Africa 0.1%, America 0.0%, Asia 10.2%), and may represent region-
specific host-directed selection. Two of the intergenic variants show strong evidence of 
continental differences (Allele frequency difference: FST score >0.2), including a 1,015 bp 
deletion in chromosome 9 upstream of gexp22 (PF3D7_0935500) (FST: 0.227; Africa 13.2%, 
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America 70.8%, Asia 41.7%) and a 605 bp deletion in chromosome 12 upstream of ap2mu 
(PF3D7_1218300) (FST 0.249; 0.2% Africa, 0.0% America, 33.6% Asia). 
 
Exploration of structural variation in anti-malarial resistance candidates 
Given that structural variation can have a significant impact on gene expression and anti-malarial 
resistance, we focused our analysis on the identification of novel structural variants in candidate 
genes (dhfr, dhps, kelch13, mdr1, gch1, crt). Because it is possible for heterogeneous duplications 
(i.e. differences in genetic copies) to display as mixed phasing calls, we extended our dataset to 
include those duplications previously excluded for highly heterozygous phasing, leading to a 
dataset that included 102,483 putative variants. To minimise the number of false positives, we 
manually verified the genomic data for all candidate regions. Overall, no high-quality SVs were 
identified in SP resistance associated dhfr (PF3D7_0417200) or dhps (PF3D7_0810800) genes, 
or artemisinin resistance associated kelch13 (PF3D7_1343700). We identify 115 specific 
duplication types containing mdr1 in 189 samples, primarily in Southeast Asia (Global 12.9%; 
Cambodia 9.5%, Myanmar 11.9%, Papua New Guinea 3.8%, Thailand 29.0%, Vietnam 5.9%), 
and near absent in Africa (Global 0.10%; Ghana 0.2%) (Figure 2), consistent with previous 
reports14. Similarly, tandem duplications are also present in KE01 (Kenya) and KH01 (Cambodia) 
within our complementary PacBio-based dataset (n=13). 
 
The whole gene duplication of gch1 (PF3D7_1224000) and a recently identified 436 bp gch1 
promoter duplication may be linked to SP resistance5. We identify 307 samples with 135 distinct 
forms of whole gene duplication across gch1 (9.9% of the total dataset) (Figure 3). Similar whole 
gene tandem duplications were present in PacBio samples for 7G8 and KH02, as a triplication in 
GB4, and as a triplication with an inverted middle copy in Dd2, this being consistent with the 
existing literature7. In contrast, 491 high quality samples are positive for the previously identified 
436bp specific ‘promoter region’ duplication (14.0% of total). We confirm this duplication being 
present at near-fixation in Malawi (89.5%), frequent in the rest of East Africa (Tanzania 78.5%, 
Kenya 31.6%), maintained in West Africa (Gambia 6.1%, Ghana 4.3%, Guinea 22.2%) and 
Central Africa (Democratic Republic of Congo 26.3%), but absent from all Asian and American 
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samples (Regional FST 0.554). No such duplication was found in any PacBio sample (n=13), 
though none of these are from Malawi. These data therefore support the gch1 promoter 
duplication being present at notable frequency across Africa, and the need for further functional 
characterisation of any potential role in SP resistance. 
 
Finally, evidence for a 22.9 kbp duplication of crt (PF3D7_0709000) is present and consistent 
across 32 samples isolated in West Africa (4.3%), specifically sub-populations isolated in Burkina 
Faso (14 samples, 29.2%), Ghana (15 Samples, 3.4%), Guinea (1 sample, 0.85%) and Mali (1 
sample, 1.8%). Those 32 samples correspond to 26 specific variants, the consensus of which 
suggests that the duplication is most likely around 22,893 bp in length, and therefore includes 
several genes (PF3D7_0708900 (sco1), PF3D7_0709000 (crt), PF3D7_0709050 (small 
nucleolar RNA), PF3D7_0709100 (cg1), PF3D7_0709200 (glp3) and PF3D7_0709300 (cg2)) 
(Figure 4). Three additional samples (2 from Ghana, 1 from Burkina Faso) also display a similar 
28.7 kbp duplication, which also includes PF3D7_0708800 (heat shock protein 110). No crt 
duplication was present in our secondary PacBio dataset (n=13). To explore the specific 
variability of crt in each sample, we calculated the abundance of resistance-associated haplotypes 
directly from raw reads, finding that both the CVMNK (chloroquine susceptible) and CVIET 
(chloroquine resistant) haplotypes were present in all 21 duplication-positive samples in 1:1 
ratios, with all other global samples generally featuring only one haplotype. Specific read counts 
suggested carriage of one chloroquine susceptible and one resistant form. It is unclear, without 
additional transcriptional analysis, whether these forms are expressed independently though we 
hypothesise that the presence of both forms may allow individual parasites to benefit from the 
resistance form whilst reducing associated fitness costs. If so, heterogeneous duplication of this 
sort may represent a more evolutionarily resilient form of crt-associated resistance.  
 
Population-Specific Variants 
Regional differences (across West Africa, Central Africa, East Africa, South Asia, Southeast Asia, 
South America) in SV frequencies were quantified with FST analysis for all high-quality variants 
(median (range): deletions 0.002 (0 - 0.613); duplications 0.001 (0 - 0.554)). A total of 153 high 
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quality variants (152 deletions and one duplication) have strong regional differences (FST >0.2), 
including: (i) an Asia-specific 59 bp deletion within the hypothetical protein PF3D7_0312900 
(FST 0.613, 69.8% South Asia, 70.9% Southeast Asia, 0.0% Rest of the World), (ii) a 40 bp South 
America-specific deletion in the putative histone deacetylase PF3D7_1472200 (FST 0.497, 54.2% 
South America, 0.0% Rest of the World), and (iii) the 436 bp gch1 promoter region duplication 
(FST 0.554, 78.0% East Africa, 17.2% Central Africa, 6.8% West Africa, 0.0% Rest of the World) 
(Supplementary Table 3). 
 
Extending our analysis to include variants within the full dataset, we identify a subset which 
display significant population specificity whilst also being supported by manual inspection of 
coverage depth and split read support. Non-drug resistance candidates (described earlier), include 
a 169 bp deletion within the rhoptry-associated membrane antigen PF3D7_0707300 (FST 0.354; 
46.0% Africa, 0.6% Asia, 0.0% America), and a 370 bp deletion in the ring-infected erythrocyte 
surface antigen PF3D7_0102200 (FST 0.213; Africa 40.3%, Asia 4.2%, America 4.2%) with 
elevation in West and Central Africa (FST 0.321; West Africa 66.1%, Central Africa 36.1%, East 
Africa 4.1%, South Asia 50.9%, Southeast Asia 2.5%, South America 4.2%). We also identify a 
near Africa-specific 586 bp deletion within the C-terminal of reticulocyte binding protein 2 
homologue b (rh2b, PF3D7_1335300) (FST: 0.334; 58.4% Africa, 12.5% America, 1.3% Asia) 
and a 29 bp deletion in rhopH2 (PF3D7_0929400) (FST 0.288; 73.7% Africa, 100% America, 
40.8% Asia), knockdown of which has been shown to inhibit parasite growth within host 
erythrocytes15. 
 
Companion visualisation tool 
To facilitate exploration of the full dataset produced by our analysis pipeline by the wider 
scientific community, we developed a companion visualisation tool contextualising these SVs 
within multiple populations (Supplementary Figure 1). This tool and its associated documentation 
are publicly available at https://pathogenseq.lshtm.ac.uk/PfGlobalSV.html. 
 
Discussion 
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This large and geographically comprehensive study of SVs in P. falciparum characterises both 
known and novel variants, the latter occurring in loci associated with antimalarial resistance, host-
pathogen interactions, and disease severity. Deletions represent the bulk of SVs (>99%) 
identified, primarily due to an abundance of shorter forms (median 26 bp) in comparison to 
duplications (median 713 bp). We find that 48.6% of high quality deletions and 65.0% of high 
quality duplications were found in single samples, in line with previous work with smaller sample 
sizes including the most recent which found that approximately half of structural variants were 
only present in one of 16 samples10. Previous studies have often overlooked the role of smaller 
structural variants, defining and applying a minimum size of 500 bp. Our results demonstrate that 
a significant number (97.7%) of high quality variants are present in the 15 to 500 bp size range, 
indicating that previous studies have under-estimated the full range of genomic variants within 
the P. falciparum genome. This finding that most SVs are under 500bp in size is consistent with 
previous studies in various species10,16. 
 
Population-specific SVs suggest evidence of localised selective pressure11. These include the drug 
resistance associated mdr1 and gch1 genes, and a striking novel 22.9 kbp duplication of the 
chloroquine resistance associated gene crt, for which samples are positive for both the CVMNK 
(chloroquine susceptible) and CVIET (chloroquine resistant) forms of the gene across multiple 
independent West African sub-populations. It is unclear whether dual-carriage of these variants 
would allow expression of both or either forms of the crt transporter, though it is likely that this 
could allow individual parasites to benefit from chloroquine resistance with a reduced fitness cost. 
This finding may also be similar to previously identified alternatively spliced forms of crt in 
eastern Sudan which were hypothesised to facilitate ‘switching’ between chloroquine resistant 
and susceptible isoforms17. Further short ~29 bp and ~430 bp deletions identified here at low 
frequency in crt may reflect the specific deletions identified in that same study.  Follow up studies, 
particularly with culture-adapted clinical isolates in which this duplication is present, are required 
to properly characterise in vitro phenotypes. We also present further characterisation of the 
promoter region duplication for the SP resistance associated gene gch1, previously identified in 
Malawi5. This additional analysis confirms the duplication is at near-fixation in Malawi, and 
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highlights its presence across Central and East Africa, including notably high frequencies in 
Tanzania, Kenya, Guinea and the DRC. Further this genetic region has been shown to be under 
positive selection in Malawi using SNP-based metrics5. 
 
Our results demonstrate that application of our pipeline can enhance the speed and capacity of 
high throughput structural variant discovery. However, this is not without limitations, especially 
as we rely upon validity of the underlying mapping, for which some regions (such as those which 
are highly variable or repetitive) are known to be difficult to characterise. In an attempt to resolve 
this issue, we excluded known highly variable regions from our analysis, such as var, rifin and 
stevor genes and subtelomeric regions. However, in doing so we prevent discovery of true variants 
within these regions, including duplications in AT-rich loci7. In addition, all identified variants 
were identified relative to the 3D7 reference strain, consistent with the approach taken in other 
studies10,11. Given that 3D7 is most likely an African strain, SVs within African samples may be 
artificially under-represented due to those variants also being present within 3D7. Further, the 
discovery stage of our pipeline inherits the limitations of those tools, such as an inability to infer 
high quality inversions. This risk was limited by prioritising those variants that were identified by 
DELLY with support from an alternative discovery software (CNVNator or Control-FREEC). 
 
The approach taken in this study, as with standard SNP discovery, requires single-genotype 
samples, preventing investigation of more complex isolates. By pre-screening for single clone 
infections and filtering on rates of predicted phasing, we were able to reduce false positive calls 
but also removed several highly likely variants that presented with a high prevalence of predicted 
heterozygous calls and potentially underestimate the total number of duplications. Notable 
candidate variants excluded from our highest quality dataset but supported by manual inspection 
of coverage depth or similar variants within the existing scientific literature include 102 putative 
deletions within the glycophorin A binding, invasion-critical gene EBA175 (PF3D7_0731500)18, 
the most prominent being a 424 bp deletion in 1,492 samples (30.5% of samples). We also identify 
a 586 bp deletion elevated in Africa (58.4% Africa, 12.5% America, 1.3% Asia) within Rh2b, a 
gene that plays a key role in erythrocyte invasion19, for which similar deletions have previously 
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been identified (and validated here) in the T996 P. falciparum line20 and samples from Senegal, 
where it is possibly associated with the utilisation of neuraminidase-sensitive invasion 
pathways21. Another is a 29 bp deletion in rhopH2 (PF3D7_0929400), with a reduced prevalence 
in Asian populations, knockdowns of which have been shown to inhibit parasite growth within 
host erythrocytes15. 
 
Our final count of 70,858 high quality specific variants assumes that each SV is distinct by their 
specific base-pair location. This means that we identify variants which arose from similar 
evolutionary events but may place insufficient emphasis on variants with a shared phenotypic 
impact. Previous studies collapsed analysis to a locus level, but risk overlooking complex 
structural variation within the same gene. This challenge was partially resolved via our secondary 
windows-based approach, whereby variants are grouped due to their presence within a 1 kbp 
window. Overall, our work presents a set of high quality structural variants, some population 
specific, which are likely to have functional consequences for drug resistance and erythrocyte 
invasion. An extended list of further structural variation requires both technological advances, 
such as low cost long read platforms with low error rates, as well as computational and algorithmic 
advances that assemble genomes to high accuracy and require less hands-on filtering. To facilitate 
further exploration of our full set of global structural variation by the wider scientific community 
we have developed a visualisation and analysis tool. This resource will assist much-needed 
genomic investigations into P. falciparum, potentially leading to biological insights for the 
development of disease control measures. 
 
Methods 
Sequence data 
Illumina raw sequence data from more than 3,500 samples in the Pf3k project were downloaded 
from the European Nucleotide Archive (see the project website, 
https://www.malariagen.net/projects/pf3k). The raw sequences were aligned to the P. falciparum 
3D7 genome using bwa-mem software, (settings: –c 100 –T 50)22, with a mean coverage of 70.7x 
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(Genic: 91.1-fold, Intergenic: 41.8-fold). SNPs and small indels (<15 bp) were called using 
SAMtools/BCFtools23 (default settings) and GATK software24 (settings: "-T UnifiedGenotyper -
ploidy 1 -glm BOTH -allowPotentiallyMisencodedQuals 2”). The overlapping set of variants 
from the two algorithms was retained for further analysis. Samples bearing abnormal coverage 
less than 20-fold or greater than 300-fold coverage were excluded to reduce false positive rates. 
Similarly, samples with complex infections were excluded. Multiplicity of infection (MOI) was 
assessed by estimating mixed SNP call abundance (cut-off >20% genotypes) and using estMOI 
software4 (MOI>1). After quality control, our dataset included 3,110 samples representing West 
Africa (n=738), Central Africa (n=360), East Africa (n=474), South Asia (n=53), Southeast Asia 
(n=1,461), and South America (n=24). The Illumina data were supplemented by PacBio 
sequences (ERP009847) from 13 laboratory strains25, including 7G8 (Brazil), IT (Brazil), HB3 
(Honduras), GA01 (Gabon), GN01 (Guinea), GB4 (Ghana), SN01 (Senegal), CD01 (Congo), 
KE01 (Kenya), SD01 (Sudan), Dd2 (Indochina), KH01 (Cambodia), and KH02 (Cambodia). 
These whole genomes were used to validate any putative deletions and duplications detected in 
discovery pipeline applied to the 3,110 samples. Manual verification of candidate duplications 
and deletions was facilitated by examination of per-base coverage plots and read pair alignments. 
 
Structural variant discovery 
Structural variants were predicted from short read alignments against the latest 3D7 reference 
assembly using DELLY (v0.7.3), which has been found to be robust across a range of organisms13.  
Variants longer than 100,000 base pairs were excluded as a conservative filter for erroneous calls, 
whilst variants identified in a subtelomeric, or highly variable loci such as var, rifin and stevor 
genes were removed due to established difficulties in accurately mapping these regions. Further, 
as 7G8 and GB4 have both Illumina and PacBio data, they were used to identify additional highly 
variable regions for exclusion, as well as assess pipeline parameters. In particular, structural 
variant discovery and analysis was performed on both the simulated and true Illumina read 
alignments for each clone, where the paired reads were aligned against their corresponding 
PacBio references, and structural variant discovery was performed with DELLY. Pipeline 
parameters were optimised for maximum concordance, and genomic regions (predominantly AT-
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rich) with high numbers of false positives excluded. Population-wide filters were also applied to 
exclude those variants with a median DELLY quality scores below 0.9, missingness >10%, 
absence of paired read support, or homozygous reference calls frequency >10%. Variants were 
also removed if they displayed a heterozygous phasing frequency greater than 30%, as these 
suggest cryptic mixed samples not identified at the SNP calling stage. Regional hotspots were 
identified using sums of samples with variants for 1 kbp sliding windows with a 500 bp step size. 
Deletions and duplications were also identified using CNVNator (v0.3.2; bin size of 400 bp)26 
and by Control-FREEC version 11.0 (window size 100 bp, window step 50 bp, ploidy of 1)27. 
Concordance statistics were derived between DELLY and the alternative methods and used to 
further filter variants that did not have support from at least two methods. 
 
Analysis of Population Statistics  
Multi-population FST statistics were calculated between continent (Africa, Asia, South America) 
and region-based sub-populations (West Africa, Central Africa, East Africa, South Asia, 
Southeast Asia, South America) for both windows and variants using Nei’s method28. 
 
Calculation of crt haplotype abundance 
To determine the variability of crt in duplication positive samples, we conducted strict match read 
counts with high quality pre-alignment reads for five specific haplotypes. Haplotype sequences 
were 25 base pairs long, and included CVMVK (TGTATGTGTAATGAATAAAATTTTT), 
CVIET (TGTATGTGTAATTGAAACAATTTTT), CVIDT 
(TGTATGTGTAATTGATACAATTTTT), CVMET 
(TGTATGTGTAATGGAAACAATTTTT), and CVMNT 
(TGTATGTGTAATGAATACAATTTTT). 
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Figure Legends 
Figure 1 
High quality variants by position, length and per-chromosome. A) Distribution of high quality 
structural variants over each chromosome. B) Distribution of deletions by size categories. C) 
Distribution of duplications by size categories. D) Distribution of distinct form of deletion across 
each chromosome. E) Distribution of distinct forms of duplication across each chromosome. 
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Figure 2 
Coverage plot confirming the whole gene duplication of mdr1. Blue represents the per base 
coverage, Orange indicates the predicted structural variant, Green indicates the gene of interest, 
Grey indicates neighbouring genes. 
 
 
Figure 3 
Coverage plot confirming the gch1 promoter duplication. Blue represents the per base 
coverage, Orange indicates the predicted structural variant, Green indicates the gene of interest, 
Grey indicates neighbouring genes. 
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Figure 4 
Coverage plot demonstrating duplication of crt. Blue represents the per base coverage, Orange 
indicates the predicted structural variant, Green indicates the gene of interest, Grey indicates 
neighbouring genes. 
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Supplementary Information 
Supplementary table 1: Summary of total sample set (n=3,110). 
Continent Region Country Count 
Total - - 3110 
Africa - - 1572 
Africa West Africa - 738 
Africa West Africa Burkina Faso 48 
Africa West Africa The Gambia 66 
Africa West Africa Ghana 446 
Africa West Africa Guinea 117 
Africa West Africa Mali 55 
Africa West Africa Nigeria 6 
Africa Central Africa - 360 
Africa Central Africa Cameroon 128 
Africa Central Africa DRC 232 
Africa East Africa - 474 
Africa East Africa Kenya 38 
Africa East Africa Madagascar 18 
Africa East Africa Malawi 353 
Africa East Africa Tanzania 65 
Asia - - 1514 
Asia South Asia - 53 
Asia South Asia Bangladesh 53 
Asia Southeast Asia - 1461 
Asia Southeast Asia Cambodia 651 
Asia Southeast Asia Laos 113 
Asia Southeast Asia Papua New Guinea 26 
Asia Southeast Asia Myanmar 134 
Asia Southeast Asia Thailand 335 
Asia Southeast Asia Vietnam 202 
America - - 24 
America South America - 24 
America South America Colombia 15 
America South America Peru 9 
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Supplementary Table 2: Most frequent structural variants by count. [large file] 
Supplementary Table 3: Most distinct variants by region-based FST values. [large file] 
Supplementary Table 4: Full list of haplotype counts for crt. [large file] 
 
 
Supplementary Figure 1: PfGlobalSV visualisation tool screenshot. 
  
104 
 
 
 
 
 
Chapter 4: 
Analysis of global long read Plasmodium falciparum genomes 
identifies novel inversions 
  
105 
 
 
  
106 
 
 
Analysis of global long read Plasmodium falciparum genomes identifies 
novel inversions 
 
Matt Ravenhall1, Ernest Diez Benavente1, Paola Florez de Sessions 2, Eloise M. Walker 
1, Martin L. Hibberd1, David A. Baker1, Susana Campino1,*, Taane G. Clark1,3,* 
 
1) Pathogen Molecular Biology Department, London School of Hygiene and Tropical 
Medicine, London WC1E 7HT, UK 
2) Genome Institute of Singapore, Singapore 
3) Department of Infectious Disease Epidemiology, Faculty of Epidemiology and 
Population Health, London School of Hygiene and Tropical Medicine, London 
WC1E 7HT, UK 
 
*Joint last authors  
107 
 
 
Graphical Abstract: 
 
 
 
  
108 
 
 
Abstract 
Structural rearrangements, including deletions, duplications and inversions, in the 
Plasmodium falciparum malaria genome underpin a range of genetic variation associated 
with antimalarial resistance and host-pathogen interactions. Established examples include 
the duplication of mdr1 associated with mefloquine resistance, and duplications of gch1 
associated with sulfadoxine-pyrimethamine resistance. In comparison, knowledge of 
inversions is incomplete, particularly as they are thought to exist within highly variable 
or repetitive regions, which are often excluded from genomic data analyses involving 
short read sequencing data. With the emergence of long read based technologies there is 
an opportunity to identify novel inversions genome-wide. We developed a pipeline for 
the robust detection of inversions and, using PacBio assemblies of 17 isolates from 14 
countries, identified 260 putative inversions (median: 17; range: 7-20, per sample) in 117 
specific forms. These inversions accounted for a median of 506 bp (range: 300-19,068 
bp) per sample, compared to a median of 20,055 (range: 841-21,038) SNPs. Whilst, 119 
(45.8%) inversions were found in highly variable gene families (rifin: 75 (30 genes), 
stevor: 8 (5 genes), var: 36 (22 genes)), others involved significant rearrangement of 
genes associated with anti-malarial resistance such as gch1 and pi4k, and erythrocyte 
invasion such as RH2b/RH2a. Our work provides the first catalogue of polymorphic 
inversions in P. falciparum and will facilitate investigations into their functions. 
Word Count: 215/300 
 
Keywords: Malaria, Plasmodium, inversions, structural variation, genomics, PacBio, 
long-read sequencing, anti-malarial resistance 
 
1. INTRODUCTION 
109 
 
 
The Plasmodium falciparum parasite inflicts a high morbidity and mortality on human 
populations in malaria endemic regions, especially Sub-Saharan Africa. Investigations of 
P. falciparum adaptation for host immune evasion, anti-malarial resistance and other 
important genetic mechanisms, have focused on single-nucleotide polymorphisms 
(SNPs), and structural variants such as duplications and deletions (Ravenhall et al. 2016, 
Cheeseman et al. 2009). However polymorphic inversions, which involve a change in 
orientation of a segment of DNA within a chromosome and represent significant genomic 
rearrangements, have been overlooked in studies of P. falciparum. In general, these 
variants consist of a specific region either being the reverse of an orthologous sequence 
in a reference genome or, when combined with duplication, of a high identity paralog. 
Such variants have the potential to impact gene expression to the point of 
pseudogenisation and underpin phenotype-enhancing events particularly when combined 
with other chromosomal rearrangements, such as duplications and deletions (Naseeb et 
al. 2016). Inversions are likely to emerge during recombination events or via the actions 
of transposable elements (Kirkpatrick et al. 2010, Mathiopoulos et al. 1999), and are 
thought to underpin the emergence of humans from other primates (Fuek et al. 2005). The 
phenotypic impacts of inversions are not limited to genic disruption as they may, when 
located within intergenic regions, define novel intrinsic terminator sites or disrupt existing 
regulatory elements (Gusarov et al. 1999). 
 
Only a handful of inversions have been studied in detail in P. falciparum and current 
knowledge about their possible functional effects is still limited. Inverted gene pairs 
include RH2a and RH2b, which are erythrocyte invasion ligands and a target of protective 
immunity (Gunalan et al. 2012), and elongation factors 1-alpha involved in binding 
aminoacyl-tRNAs to the ribosomal acceptor site during translation (Dvorin et al. 2010, 
Riis et al. 1990). Inversions are also thought to play a key role in the active rearrangement 
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of highly variable genes involved in host-pathogen interactions such as those of the var, 
stevor, and rifin gene families, and have previously been identified in the apicoplast of 
Plasmodium chabaudi chabaudi (Sato et al. 2013). Knowledge of the full extent of 
inversions, their global diversity, and effect upon the evolution of the P. falciparum 
genome, is limited. This is despite the known roles of duplications and deletions in 
conveying anti-malarial resistance factors such as mdr1 and gch1 (Borges et al. 2011, 
Nair et al. 2008). 
 
Previously the discovery of putative inversions has been limited to candidate regions and 
to short read based analytical approaches that have difficulties in resolving particularly 
repetitive or variable regions, especially for an AT-rich genome such as P. falciparum. 
With the development of newer, long read based sequencing platforms such as PacBio 
Single Molecule Real Time (SMRT) it is now possible to construct a genome that reduces 
the impact of poor de novo assembly in repetitive regions, but also decreases the reliance 
on a reference genome where an inversion may not be present. Therefore, we combined 
a PacBio long read sequencing approach of P. falciparum samples with an in-depth 
inversion discovery pipeline that utilises whole chromosome alignment. Our dataset 
consists of seventeen strains sourced from eleven countries, four of which were sequenced 
and assembled in-house. In total we identified 260 putative inversions in 117 specific 
forms, two of which include genes associated with anti-malarial resistance. Our findings 
highlight the potential role of putative inversions in known variable genes, such as var, 
rifin, and stevor, represent a robust method for detecting ancestral paralog inversions such 
as RH2a and RH2b, and point towards a novel tandem inversion of pi4k that may have an 
impact on anti-malarial resistance. 
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2.MATERIALS AND METHODS 
2.1. Samples and assembly 
DNA was extracted from the cultures of four lab strains (K1, Thailand; D10, Papua New 
Guinea; NF54, Africa; T996 Thailand), and sequenced on the Pacific Biosciences 
(PacBio) RSII long read technology at the Genome Institute of Singapore. Sequencing 
reads were assembled using Hierarchical Genome Assembly Process HGAP2 
implemented in the SMRT Portal software suite. Short low confidence contigs (length 
<1000 or identity < 90%) were removed from subsequent analyses. The overlaps between 
the start and end of large contigs were found by self-aligning using Mummer software 
(Delcher et al. 1999) and removed using in-house scripts. Contigs were aligned, scaffolds 
inferred, reordered and, if needed, reverse-complemented according to the 3D7 reference 
using the mummer tool and in-house scripts. Following this the reads were realigned to 
the scaffolds to improve the consensus concordance, leading to complete chromosomes. 
Chromosome-wide assemblies of PacBio sequence data were also available for a further 
13 strains (accession number ERP009847), including five laboratory strains 7G8 (Brazil), 
Dd2 (Indochina), GB4 (Ghana), HB3 (Honduras), IT (Brazil), and eight field isolates 
GN01 (Guinea), SN01 (Senegal), CD01 (Congo), GA01 (Gabon), KE01 (Kenya), SD01 
(Sudan), and KH01 and KH02 (Cambodia) (see Otto et al. 2018).  
 
2.2. Inversions discovery and verification 
For each of the 17 strains, the whole chromosome alignments were mapped against the 
3D7 reference (v3) using nucmer (Delcher et al. 1999) to identify genomic regions of 
high identity (greater than 75%). Additional filtering was based on inclusion of reverse 
alignments, sequence length greater than 300 bp, and 3D7-strain mapping distances 
within 50 kbp. The pipeline and associated scripts are available 
(https://github.com/mattravenhall/PfINV). Manual verification was assisted through 
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alignment of candidate regions with BLAST (Camacho et al. 2009), as well as the 
multiple alignment of orthologous sequences using ClustalO (Sievers et al. 2011). SNPs 
were inferred using snp-sites software (Page et al. 2016), and their impacts were predicted 
using functions from our ‘bio’ Python module (available at 
https://github.com/mattravenhall/bio). This package was also used for the dissection of 
palindromic motifs within candidate sequences. 
 
3. RESULTS 
3.1. Inversions are rare and long variants 
We identify 260 putative inversions with greater than 75% sequence identity and 92 with 
greater than 95% identity (Figure 1d). The inversion set (n=260) represents a mean 
number per sample of 15.3 (±4.7) (median: 17; range: 7-20) (Table 1) and corresponds 
to 117 distinct forms with a median length of 506 bp (mean 1,577.3 bp) (Supplementary 
Table 1). In comparison we identified a median of 20,055 SNPs (841 to 21,038) and a 
median of 29,630 (range: 4,249 to 38,141, mean: 23,281.1) bp of inversions per sample, 
with a ratio of number of SNPs to total inversion length close to one (mean: 1.38, median: 
0.66; range: 0.02-4.85). This suggests an equivalent proportion of the P. falciparum 
genome is impacted by inversions as by SNPs, though SNPs are likely to emerge far more 
often. There was no significant difference in the number of inversions between the three 
primary continents (Africa (n=8): 16.4 ±4.4, Asia (n=5): 15.2 ±5.9, America (n=3): 13.3 
±5.0; Kruskal-Wallis P=0.570), though sample size is limited. 
 
The majority of putative inversions (n=217, 83.5%) are present within intergenic regions 
or the highly variable members of the rifin (75 inversions; 30 genes), stevor (8 inversions; 
5 genes), and var (36 inversions; 22 genes) gene families (Figure 1b). These inversions 
are significantly shorter than the others (median length: intergenic or highly variable 
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regions 482 bp, vs. other regions: 5,329 bp; Wilcoxon test P=2.30x10
-14), with generally 
low identities relative to 3D7 (mean: 87.5%, median: 87.4%) suggesting non-recent or 
more complex inversion events. We also identify two historic inversion/duplication 
events present within RH2a/RH2b and elongation factor 1-alpha (PF3D7_1357000 and 
PF3D7_1357100). Further, two sample specific inversions are present in Dd2, where we 
identify the previously characterised gch1 ’sandwich’ inversion (Miles et al. 2016), and 
in GB4 where we identify a novel tandem inversion of anti-malarial drug target pi4k. 
Overall, we identify 119 variants within highly variable genes, 98 within intergenic 
regions, 42 associated with RH2a/RH2b, 11 associated with elongation factor 1-alpha, 1 
of gch1 and 1 of pi4k.  
 
3.2. Highly variable genes contain numerous putative inversions 
Of the putative inversions within 30 different rifin genes, 15 are present in single samples. 
Two genes (PF3D7_0402500, 12 samples; PF3D7_0402700, 14 samples) contain 
inversions in the majority of samples. For PF3D7_0402500, we identify inversions in 12 
samples, six (GB4, KE01, IT, Dd2, NF54, T996) with short forms (INV019; 401 bp) and 
six (7G8, GA01, GN01, K1, KH01, KH02) with longer forms (INV018; 562 bp), 
including one in Guinean GN01 with a particularly high identity (98.4%). Similarly, for 
PF3D7_0402700, nine samples (IT, KE01, KH02, T996, 7G8, Dd2, GA01, GN01, NF54) 
contain a short form (INV020; 403 bp), whilst five (CD01, GB4, K1, KH01, SN01) have 
a longer form (INV021; 570 bp). Given the similar lengths to those in PF3D7_0402700, 
these genes may represent a tandem inversion or duplicated domain whereby INV018 
pairs with INV021 and INV019 pairs with INV020. Alignment of the two genes supports 
this, with the pair sharing an approximately 800 bp region (from 350/450 to 1100/1200 
bp, 61.6% coverage, 81.6% identity) (Figure 2). Of the remaining putative rifin 
inversions, the KH01 strain displays two inverse matches for specific regions in both 
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PF3D7_0114700 and PF3D7_0200500. All four forms (INV005a, INV005b, INV008a, 
INV008b) have modest identities (PF3D7_0114700: 84.49% and 84.43%, 
PF3D7_0200500: 80.82% for both), suggesting the presence of two KH01-specific 
imperfect duplications within these genes. Manual inspection of those candidate regions 
found that INV005a/b aligned to the start and upstream regions of multiple rifin genes 
across several chromosomes, with INV008a/b similarly being found to align to the ends 
of multiple rifin genes.  This suggests that these specific regions correspond to shared 
domains across a subset of rifin genes, with INV005a/b perhaps also including shared 
promoter regions. A similar feature is present within the Papua New Guinea laboratory 
strain D10 whereby three 329 bp inverted regions (INV073a, INV073b, INV073c) again 
with acceptable identities (84.8% for all three) are present. Further alignment of the D10 
region against 3D7 found that the core sequence matched multiple var genes, suggesting 
that D10 has multiple repeats of a common var domain in this copy of PF3D7_1100300. 
 
Very few isolates share inversions within var genes, with thirty-two variants being 
present once and two being present twice. This diversity, and the generally low identities 
for these putative inversions (mean: 86.0%, median: 86.1%) reflect the high level of 
variability within this gene family. Two notable exceptions are PF3D7_0600600, in 
which we identify six putative inversions (INV033 to INV038) in five samples, and 
PF3D7_0100500, where we identify a 482 bp inversion (INV003; 97.3% identity) in the 
Gambian GA01 strain. This high identity inversion appears to correspond to a duplicate 
inversion 18 kb upstream and a number of similar regions around the genome, suggesting 
that the sequence may represent some form of common motif or transposable element. 
For PF3D7_0600600, we observe a heterogeneous group of six putative inversions, two 
of which (INV033 and INV037) are present in the Kenyan KE01 strain, whilst the other 
four (INV034, INV035, INV036, and INV038) are in NF54, KH02, K1, and CD01. 
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Though two variant pairs (INV035 with INV036, and INV037 with INV038) share 
starting breakpoints in KH02 with K1, KE01 and CD01, there is limited general 
concordance for either variant positions or length. In general, this highlights the highly 
diverse variability of PF3D7_0600600. 
 
Even fewer putative inversions are present within stevor gene family members, with five 
samples containing variants within five genes, though the degree of identity is relatively 
low (mean: 83.79%, median: 82.91%). Of those, the IT strain has candidate inversions in 
three genes, a 651 bp region in PF3D7_0631900 (INV039), a 932 bp region in 
PF3D7_1254300 (INV081), and a 1012 bp region in PF3D7_1300900 (INV093). A 
similar 959 bp inversion in PF3D7_1300900 is present in the Guinean GN01 strain. These 
inversions are all generally low identity with broader alignment showing that these 
specific sequences are generally shared across multiple stevor genes. Finally, three 
African samples (GB4, GA01, GN01) contain a putative inversion (INV117) within the 
same region of PF3D7_1400700, each approximately 1 kbp in length. Poor alignment of 
these flanking regions and the general repetitiveness of this region suggests that INV117 
may represent a detection of an inverted nearby gene with relatively high similarity to 
PF3D7_1400700. 
 
3.3. Inverted paralogs play a significant role in P. falciparum genome 
Our approach identified two gene pairs (RH2a/RH2b and elongation factors 1-alpha) that 
have emerged through historical duplication and inversion. RH2a and RH2b represent the 
classic example of a tandem inverted duplication in P. falciparum, being absent from 
other Plasmodium species (Otto et al. 2014) and bearing a key role in erythrocyte invasion 
(Duraisingh et al. 2003). The pair consists of two highly similar genes that emerged from 
the inverted duplication of their ancestral gene and therefore represent high identity 
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inverted paralogs of one another. Putative inversions were identified in 13 samples (7G8, 
GB4, Dd2, HB3, IT, CD01, KE01, GA01, SD01, GN01, K1, NF54, T996), but absent in 
the remaining four isolates due to RH2b being fully deleted in KH01 and D10, partially 
deleted in the 3’ region in SN01, and having minor deletions in KH02. We also identify 
putative inversions of the intergenic regions between RH2a and RH2b, and upstream 
towards and including a ~200 bp region of RH6. These likely represent components of 
the original inversion duplication between which later variation has occurred. 
 
A lesser-known example of a historic tandem inversion is elongation factors 1-alpha 
(PF3D7_1357000, PF3D7_1357100), which presents with similarly high identities as 
RH2a and RH2b (mean: 99.06%, median: 99.51%). This gene pair are, as with Rh2a and 
Rh2b, a well-established example of a tandem duplication where one of the pair is 
inverted relative to the other (Vinkenoog et al. 1998). This pair is also intriguing due to 
the presence of a bi-directional promoter within the intergenic region between the two 
genes (Fernandez-Becerra et al. 2003). Putative inversions were detected in sixteen 
samples, in which the majority have a 4,433 bp variant. These were absent in T996, and 
the Congolese CD01 strain has shorter 1,354 and 1,356 bp inversions (INV111 and 
INV113), which are present for each gene separately. This emphasises the non-inverted 
nature of the intergenic region between the gene pair, as this region aligns near perfectly 
with the reference but in only one direction. 
 
3.4. Dd2 features a ‘sandwich’ inversion of YHM2, PF3D7_1223900, and gch1 
Our approach highlighted a more complex rearrangement containing gch1 in which a 
tandem triplication event contains an inverted copy (INV080) between two non-inverted 
copies of the region. We refer to this rearrangement as a ‘sandwich’ inversion for ease of 
reference. The Dd2 region therefore includes the wildtype YHM2 (PF3D7_1223800), 
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PF3D7_1223900, and gch1 (PF3D7_1224000) region followed by a near-identical 
inversion of those three genes, completed by a third set of the three genes in wildtype 
arrangement (Figure 3a). This feature represents a 5,306 bp region of Dd2, corresponding 
to a 5,329 bp region of our 3D7 reference, with 98.6% identity (Supplementary table 1). 
This feature represents the inverted segment of the previously identified Dd2 tandem 
triplication (Miles et al. 2016). This form of inversion appears to be unique to Dd2 and 
may therefore represent variation acquired within the laboratory after initial collection. 
Phenotypically the inclusion of PF3D7_1223800 (YHM2) and PF3D7_1223900 is curious 
as it could suggest some secondary impact alongside that of gch1 duplication, or at least 
a limited negative impact on the preserved genotype. The preservation of all three genes 
also supports this feature having occurred as a result of a single triplication event, rather 
than multiple recombination events. 
 
3.5. GB4 contains a putative ‘sandwich’ inversion of PF3D7_0509700, PI4K and 
PF3D7_0509900 
A ‘sandwich’ inversion is present within a ~7 kbp region of GB4 with the inverted region 
sharing 97.7% identity (INV027). The central inversion (PI4K_B) includes two genes, 
one of unknown function with a predicted C-terminal Nse4_C domain (PF3D7_0509900) 
and phosphatidylinositol 4-kinase (pi4k, PF3D7_0509800), the target of 
imidazopyridines (McNamara et al. 2013). The third duplication (PI4K_C) also includes 
a section of PF3D7_0509700 (a conserved unknown protein) (Figure 3b). The full 
PF3D7_0509700 may be duplicated but an assembly gap between the second (PI4K_B, 
inverted) and third (PI4K_C, longer) duplication makes full resolution of the region 
difficult. Both PI4K_B and PI4K_C contain SNPs encoding putative premature stop 
codons, whilst PI4K_A contains some minor deletions relative to 3D7, particularly in 
repetitive domains. PI4K_B also lacks a 111 bp segment in its 5’ region. It seems probable 
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that PI4K_B and PI4K_C are non-functional alleles of wildtype PI4K. If PI4K_A is also 
shown to be non-functional, this ‘sandwich’ inversion may represent significant 
disruption of the region rather than an increase in expression, as is classically assumed 
with duplication events. Evolutionarily, the presence of PF3D7_0509700 in PI4K_C, but 
not PI4K_B, suggests that this triple duplication arose through at least two recombination 
events. Repeated recombination of the region would be consistent with a process of 
pseudogenisation following the removal of preserving selection. 
 
3.6. Intergenic regions contain inversions 
Ninety-eight inversions are present in intergenic regions of 3D7, and most bear high 
identity (mean: 92.3%, median: 94.2%, range: 76.5-99.05%). Within this subset are a 
number of distinct regions, which reflect variation stemming from low complexity, local 
inversions as well as constituting parts of larger genic inversions. Twenty-six putative 
inversions exist within chromosome 13 (128,289 to 128,794 bp) but bear generally lower 
identity scores (mean: 88.5%, median: 89.6%, range: 76.5-97.7%) with the exception of 
three particularly high identity variants in Kenyan KE01 (INV095, 300 bp, 97.7%), 
Congolese CD01 (INV096, 302 bp, 97.7%) and Honduran HB3 (INV096, 302 bp, 
96.2%). In general, this core sequence has low complexity and high repetition with 
manual realignment highlighting similarity between this region and an inverse sequence 
~5 kbp upstream. Variants within this region would therefore reflect local similarity with 
those of high identity seeming to reflect a true local 300 bp inversion in KE01, CD01, 
and HB3. 
 
A subset of intergenic inversions hint at possible errors in the 3D7 reference, likely due 
to its assembly from short read sequences. Specifically, whilst manual alignment of 
INV110, INV114, and INV115 found high identity inverted matches for those specific 
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sequences (INV110: mean: 98.9%, median: 99.0%, range: 98.5 - 99.0%; INV114: mean: 
95.7%, median: 95.9%, range: 91.3 - 97.6%; INV115: mean: 97.3%, median: 97.6%, 
range: 94.5-99.1%), this did not hold true for their flanking regions. All three candidate 
inversions are present in multiple sequences (INV110: eleven isolates: GB4, HB3, Dd2, 
IT, KE01, CD01, SD01, GA01, NF54, K1, T996; INV114 and INV115: twelve isolates: 
7G8, GB4, HB3, Dd2, IT, KE01, CD01, SD01, GA01, NF54, K1, T996) with high 
identity for both the publicly available and in-house PacBio sequences, ruling out the 
possibility of contamination and the sequence is too specific, extensive and isolated for a 
possible sequencing error. Realignment and manual inspection of these variants and 1,000 
bp flanking regions found high identity alignment (>95%) with Plasmodium sp. gorilla 
clade G1 genome assembly (LT963426), a PacBio assembly for a species closely related 
to P. falciparum. This observation suggests that the corresponding genomic region within 
3D7 may be incorrectly assembled, potentially due to repetitive sequences that PacBio is 
better able to resolve. 
 
4. DISCUSSION  
Inversions within the P. falciparum genome are generally rare, with an average of ~15 
per sample, and can generally be classified into three forms: classic, tandem, and 
sandwich. Classic inversions refer to those examples where a specific sequence has been 
flipped in situ without duplication. Tandem inversions refer to tandem duplications in 
which one of the copies is flipped. Whilst, sandwich inversions refer to triplication events 
or beyond in which the middle copy is reversed relative to the other copies. Classic 
inversions are particularly rare, with no clear genic examples being identified in this 
study, though a number of intergenic examples were present (such as INV110); instead 
inversions seem to occur in combination with duplication events. Tandem inversions 
include the classic examples of RH2a/RH2b and elongation factors 1-alpha, but also an 
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array of intergenic or highly variable regions. Finally, only two examples of sandwich 
inversions were observed, the previously identified inversion of gch1 within a triplication 
in Dd2, and the novel inversion of pi4k in GB4. Both represent variants within laboratory 
strains with none such examples identified within our field isolates. 
 
As may have been expected given the potentially disruptive consequences of this form of 
genomic rearrangement, most putative inversions were present within intergenic or highly 
variable regions. The majority are of lower identity, suggesting the detection of either 
pseudo-inverted regions or older inversions with depreciated identities. Despite this 
challenge, we identify several specific, high identity inversions that likely represent true 
inversion-based recombination of these genes. The use of PacBio SMRT long read 
sequencing represents a significant opportunity to resolve some genetic regions that have 
been previously overlooked due to usual exclusion of these regions, and follow-up 
functional work may present insights into virulence or host immune evasion. The P. 
falciparum genome is host to three families of highly variable genes, the products of 
which are expressed on the surfaces of infected human erythrocytes conveying key roles 
in malaria pathology (Niang et al. 2009, Gardner et al. 1996, Kyes et al. 1999).  Given 
their exposure to the human immune system, there is significant selective pressure driving 
these genes to be hyper-variable with this variability consisting of SNPs, indels, and larger 
genetic rearrangements. Inversions have been presumed to play a role, but little is known 
about the extent. A greater understanding of the structural variation for these hyper-
variable genes is one key aspect to understanding their role in infection and immune 
evasion, and therefore in informing future vaccine or anti-malarial strategies. 
 
Inversions were observed across several samples for specific regions of the same genes 
or intergenic regions, suggesting the detection of specific sub-domains within these 
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diverse genes. One such example is that of the rifin pseudogenes PF3D7_0402500 and 
PF3D7_0402700, for which each contains a pair of mirrored domains approximately 400 
and 560 bp in length (INV019 with INV020, and INV018 with INV021). This specificity 
of similarity is striking, and points towards a possible direct functional relationship 
between these two genes. Similar selection signals also appear to be present for intergenic 
inversions such as INV110, a 579 bp inversion downstream of the putative chromosome 
condensation regulator PF3D7_1356600. The functional implications of INV110 are 
unclear, as the specific region is intergenic, but its presence within multiple samples 
suggests some level of active conservation. 
 
One initially unexpected finding of our study was the detection of novel tandem inverted 
duplications similar to RH2a/RH2b and elongation factors 1-alpha, one example being 
PF3D7_0402500 and PF3D7_0402700. This form of structural variant is uncommon but 
significant, and arguably represents an under-appreciated component of P. falciparum 
evolution. This is particularly compelling when considering the classic example of 
RH2a/RH2b, a gene pair specific to P. falciparum, which have been linked to sialic acid 
independent invasion, and erythrocyte binding (Gunalan et al. 2012, Desimone et al. 
2009, Sahar et al. 2011). Further, two specific regions contain unique sandwich 
inversions: the inverted duplication of gch1 in Dd2 (INV080) and of pi4k in GB4 
(INV027). Curiously both genes have significant roles in anti-malarial resistance; for 
gch1, whole gene and upstream duplications have been associated with late stage 
resistance to sulfadoxine-pyrimethamine (SP) (Borges et al. 2011, Ravenhall et al. 2016), 
whilst pi4k is the target of imidazopyrazines (McNamara et al. 2013). Both are also lab 
strains rather than field isolates, suggesting that these inversions may have emerged 
within the lab after initial isolation. The sandwich inversion of gch1 in Dd2, in which a 
triplication of gch1 features an inverted central copy, has been previously characterised 
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in some detail (Miles et al. 2016), albeit primarily within the context of duplication given 
the role of similar gch1 duplications in SP resistance. In contrast, the inverted duplication 
of PI4K appears to be novel, and less clearly resolved as a triplication due to the presence 
of an assembly gap between PI4K_B and PI4K_C. Manual inspection suggests that this 
region may be undergoing pseudogenisation in GB4, owing to the presence of putative 
premature stop codons within PI4K_B and PI4K_C. It is unclear whether the SNPs 
present within PI4K_A would also lead to a loss of function. The third PI4K_C section of 
the triplication also includes a copy of PF3D7_0509700, which has been shown to bind 
with alternative splicing regulator PfSR1 (Eschar et al. 2015), however the 
aforementioned assembly gap makes full investigation difficult. It is similarly unclear 
whether triplication of PF3D7_0509900 has a phenotypic impact. 
 
Inversions play an understated role in P. falciparum genomics, but the phenotypic impact 
of this variation remains poorly characterised. Our study represents a step towards a 
broader understanding of P. falciparum inversions around the globe for both specific 
candidates, particularly those associated with anti-malarial resistance, and for identifying 
patterns within the diverse erythrocyte surface exposed var, stevor, and rifin gene 
families. We also demonstrate the power for long read sequencing approaches in 
identifying novel inversions within assemblies through whole chromosome alignment 
and encourage broader use of similar approaches for discovery in larger sample sets.  
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Figure Legends 
Figure 1: Summary panel of inversions: (A) Genomic positions of each inversion, (B) 
Distribution of locus type4, (C) Distribution of inversion sizes, (D) Distribution of 
identities per inversion. 
 
 
Figure 2: Schematic representation of orthologous regions of PF3D7_0402500 and 
PF3D7_0402700, including predicted inversion pairs. 
                                                 
4 Inversion definitions: Tandem Inversion = Forward copy followed by reverse copy, Sandwich = Reverse 
copy between two forward copies, Intergenic = Outside a coding region, Historic Tandem Inversion = 
Previously characterised inversions present in all P. falciparum relative to other species, Highly Variable 
Region = Present within a known highly variable gene. 
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Figure 3: Schematic candidate diagrams for inversions of: (A) gch1 in Dd2, (B) pik4 
in GB4. Dashed lines indicate a gap between contigs in the strain assembly. 
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Table 1: Summary of inversions per sample. *long term cultures; PNG = Papua New 
Guinea. 
Isolate Location 
Total 
Inversions 
Intergenic 
Inversions 
Highly Variable 
Inversions 
(rifin, var, stevor) 
Notable Genic 
Inversions 
7G8* Brazil 8 2 3 (3, 0, 0) RH2a/b 
IT* Brazil 18 6 8 (3, 2, 3) RH2a/b, EF1a 
HB3* Honduras 14 9 2 (1, 1, 0) RH2a/b, EF1a 
NF54* Africa 20 9 7 (5, 2, 0) RH2a/b, EF1a 
GA01 Gabon 20 10 7 (4, 2, 1) RH2a/b, EF1a 
GN01 Guinea 15 4 10 (5, 3, 2) RH2a/b 
GB4* Ghana 18 10 4 (2, 1, 1) RH2a/b, EF1a, PI4K 
SN01 Senegal 7 1 6 (4, 2, 0) - 
CD01 Congo 20 9 6 (3, 3, 0) RH2a/b, EF1a 
KE01 Kenya 17 6 7 (4, 3, 0) RH2a/b, EF1a 
SD01 Sudan 14 8 4 (2, 2, 0) RH2a/b, EF1a 
Dd2* Indochina 19 8 7 (5, 2, 0) RH2a/b, EF1a, gch1 
KH01 Cambodia 11 0 11 (10, 1, 0) - 
KH02 Cambodia 7 2 5 (2, 3, 0) - 
K1* Thailand 19 5 11 (8, 3, 0) RH2a/b, EF1a 
T996* Thailand 20 7 10 (8, 1, 1) RH2a/b 
D10* PNG 13 2 11 (6, 5, 0) EF1a 
 
Supplementary table 1: Full list of inversions. HTI = Historic tandem inversion; HVR 
= Highly variable region; SI = Sandwich inversion; TI = tandem inversion; Int = 
intergenic. [large file] 
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Novel genetic polymorphisms associated with severe malaria and 
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Supplementary Information 
Supplementary Figure 1: Population Structure. 
 
 
Supplementary Table 1: Full list of significant SNP associations, including odds ratios 
and minor allele frequencies. [large file] 
Supplementary Table 2: Structural variation identified within regions consisting of 
GWAS associations, known malaria candidates and sites under selection (iHS, XP-
EHH). 
SNP Gene Location Total Del. Dup. Ins. Inv. Presence in 1000 Genomes populations 
IL23R and IL12RB2 1: 67,632,083-67,862,583 GWAS 
1 
(1) 
1 
(1) 
- - - 
1 deletion; 1 total case 
(1 East Asian) 
RYR2 1: 237,205,505-237,997,288 GWAS 
49 
(51) 
9 
(11) 
- - 
40 
(41) 
8 deletions; 23 total cases 
(14 Africans, 6 East Asians, 2 Americans, 1 European 
MAP1B 5: 71,403,061-71,505,395 GWAS 
2 
(9) 
2 
(9) 
- - - - 
KLHL3 5: 136,953,189-137,071,779 GWAS 
63 
(153) 
63 
(153) 
- - - 
1 deletion; 15 total cases 
(3 South Asians, 9 Europeans, 3 Americans) 
HBB 11: 5,246,694-5,250,625 GWAS/ Candidate - - - - - 
4 deletions; 14 total cases 
(3 East Asians, 6 African) 
LINC00943/4 12: 127,214,333-127,256,957 
GWAS 
- - - - - 
2 deletions; 3 total cases 
(1 South Asian, 1 African, 1 East Asian) 
LIPG 18: 47,087,069-47,119,272 
GWAS 13 
(13) 
13 
(13) 
- - - - 
ZNF536 19: 30,719,197-31,204,445 
GWAS 
2 
(3) 
2 
(3) 
- - - 
4 deletions, 1 ALU deletions; 200 total cases 
(117 Europeans, 44 Americans, 32 South Asians, 6 Africans, 1 East 
Asian) 
ATP2B4 1: 203,595,689-203,713,209 Candidate 
25 
(25) 
25 
(25) 
- - - 
1 deletion; 857 total cases 
(246 South Asian, 194 East Asian, 177 African, 159 European, 81 
American) 
USP38 4: 144,106,070-144,144,983 Candidate - - - - - - 
FREM3 4: 144,498,455-144,621,828 Candidate 
28 
(29) 
28 
(29) 
- - - 
1 deletion; 9 total cases 
(4 East Asians, 5 Europeans) 
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GYPE, GYPB, GYPA  4:144,792,020-145,061,904 Candidate 
55 
(59) 
31 
(35) 
24 
(24) 
- - 
8 deletions, 2 duplications; 133 total cases 
(102 Africans, 9 South Asians, 7 Americans, 14 East Asians, 1 
European) 
Major Histocompatibility 
Complex 
(including HLA) 
6: 28,477,796-33,448,353  
Candidate/iHS/XP-
EHH 
2333 
(3337) 
1711 
(2552) 
1711 
(2552) 
1711 
(2552) 
1711 
(2552) 
101 deletions, 13 duplications, 8 CNVs, 6 ALU deletions; 60,948 
total cases 
(all samples) 
ABO 9: 136,125,788-136,150,617 Candidate 
9 
(21) 
1 
(1) 
6 
(6) 
1 
(13) 
1 
(1) 
1 deletion; 20 total cases 
(17 Africans, 3 American) 
MARVELD3 16: 71,660,064-71,676,017 Candidate 
5 
(5) 
5 
(5) 
- - - 
1 deletion; 4 total cases 
(3 Africans, 1 American) 
HBA2 16: 222,846-223,709 Candidate 
3 
(3) 
3 
(3) 
- - - 
2 deletions; 274 total cases 
(192 Africans, 35 East Asians, 23 South Asians, 17 Americans, 4 
Europeans) 
HBA1 16: 226,679-227,521 Candidate 
1 
(1) 
1 
(1) 
- - - 
3 deletions; 297 total cases 
(192 Africans, 25 East Asians, 23 South Asians, 17 American, 4 
Europeans) 
RORC, C2CD4D, THEM5 1: 151,792,842-151,817,543 iHS 
2 
(2) 
2 
(2) 
- - - - 
DUSP19, NUP35 2: 183,699,180-185,281,789 iHS 
139 
(280) 
101 
(213) 
- - 
38 
(67) 
27 deletions, 5 duplications, 1 CNV, 1 inversion; 1,302 total cases 
(346 Africans, 209 Europeans, 202 East Asians, 185 Americans, 
139 South Asians) 
ERBB4 2: 212,380,286-213,576,272 iHS 
65 
(236) 
59 
(207) 
- 
5 
(28) 
1 
(1) 
22 deletions, 7 duplications, 2 CNVs, 1 ALU deletion, 1 inversion, 
1 insertions; 4,165 total cases 
(all samples) 
MCUR1 6: 13,786,789-13,814,800 XP-EHH 
2 
(2) 
2 
(2) 
- - - 
1 deletions; 1 total case 
(1 African) 
PPARD, MKRNP2, FANCE, 
TEAD3, RPL10A, TULP1, 
FKBP5, ARMC12 
6: 35,337,931-35,732,137 iHS 
101 
(179) 
94 
(170) 
3 
(3) 
3 
(5) 
1 
(1) 
6 duplications, 4 deletions, 1 CNV; 2,806 total cases 
(629 Africans, 473 East Asians, 451 Europeans, 443 South Asians, 
332 Americans) 
GCLC 6: 53,362,139-53,481,768 XP-EHH 
3 
(4) 
3 
(4) 
- - - 
2 deletions, 3 total cases 
(1 African, 2 Europeans) 
RIMS1 6: 72,805,811-72,828,559 iHS 
1 
(1) 
1 
(1) 
- - - 
1 duplication, 1 CNV; 35 total cases 
(16 Europeans, 10 Americans, 6 South Asians, 2 Africans, 1 East 
Asian) 
POM121L12 7: 53,103,349-53,104,617  XP-EHH - - - - - - 
SYNJ2BP, ADAM21, ADAM20 14: 70,838,148-71,001,732 XP-EHH 
21 
(21) 
21 
(21) 
- - - 
1 deletion; 1 total case 
(1 East Asian) 
ZFHX3 16: 72,916,326-73,133,159 iHS 
3 
(3) 
3 
(3) 
- - - 
3 deletions; 5 total cases 
(2 Europeans, 1 South Asian, 1 African, 1 East Asian) 
ITGAE 17: 3,632,836-3,689,132 iHS 
3 
(9) 
3 
(9) 
- - - - 
ERG, ETS2 21: 39,751,949-40,196,879 XP-EHH 
23 
(41) 
21 
(38) 
- 
2 
(3) 
- 
7 deletions, 1 ALU deletion, 1 duplication; 2,727 total cases 
(457 Europeans, 412 Africans, 379 South Asians, 296 Americans, 
220 East Asians) 
 
Supplementary Table 3: Candidate SNP associations. 
SNP ID Gene Location Min. P Model Case MAFs 
Control 
MAFs 
Trios 
MAFs 
Kenya 
MAFs 
Nigeria 
MAFs 
Global 
MAFs 
rs334 HBB 11:5248232 2.61x10-13 * Heterozygous 0.020 0.080 0.026 0.101 0.139 0.027 
rs4951074 rs10900585 
rs55868763 rs1541255 
ATP2B4 
1:203660781 
1:203654024 
1:203652140 
1:203652141 
5.19x10-1 
2.07x10-1 
4.20x10-1 
4.20x10-1 
Dominant 
Additive 
Dominant 
Dominant 
0.323 
0.338 
0.330 
0.330 
0.340 
0.375 
0.354 
0.354 
0.285 
0.327 
0.298 
0.297 
0.374 
0.414 
0.394 
0.394 
0.421 
0.481 
0.417 
0.417 
0.152 
0.172 
0.150 
0.150 
rs149914432 
rs186790584 
rs186873296 
FREM3 
4:144666678 
4:144680140 
4:144702474 
1.73x10-2 
1.74x10-2 
2.28x10-2 
Recessive 
0.032 
0.031 
0.030 
0.058 
0.054 
0.053 
0.024 
0.024 
0.024 
0.015 
0.005 
0.005 
0.005 
0.005 
0.005 
0.002 
0.001 
0.001 
rs4266246 
rs28459062 
USP38 
4:143971242 
4:144039139 
2.21x10-4; 
4.66x10-2 
Additive 
Recessive 
0.316 
0.150 
0.229 
0.184 
0.285 
0.126 
0.258 
0.207 
0.204 
0.213 
0.438 
0.092 
Deletion GYPE, B, A 4:144801719-145041744 3.01x10-1 Additive 0.001 0.000 0.004 - - - 
rs1264362 
rs2523589 
HLA_B_07 
HLA 
6:30776590 
6:31327334 
6:31431272 
1.90x10-3 
9.33x10-5 
6.49x10-5 
Additive 
Dominant 
Dominant 
0.200 
0.394 
0.394 
0.246 
0.483 
0.484 
- 
- 
- 
0.131 
0.288 
- 
0.032 
0.301 
- 
0.153 
0.356 
- 
rs8176746 
rs7853989 
rs1053878 
rs8176719 
ABO 
9:136131322 
9:136131592 
9:136131651 
9:136132908 
1.89x10-1 
2.27x10-1 
3.98x10-1 
8.69x10-2 
Dominant 
Dominant 
Heterozygous 
Additive 
0.164 
0.166 
0.261 
0.326 
0.149 
0.155 
0.267 
0.294 
0.156 
0.158 
0.292 
0.311 
0.162 
0.172 
0.202 
0.288 
0.171 
0.171 
0.231 
0.231 
0.153 
0.164 
0.133 
0.344 
rs2334880 MARVELD3 16:71653637 7.09x10-1 Dominant 0.446 0.449 0.441 0.470 0.407 0.157 
α-thalassemia deletion HBA1, HBA2 - 1.80x10-2 Recessive 0.264 0.318 - - - - 
 
Supplementary Table 4: Regions under potential whole population positive selection 
(absolute iHS > 4). 
Chromosome Location No. of SNPs Gene 
1 101851482 1 RP11-157N3.1 (lincRNA) 
1 103755600 1 Intergenic 
1 109070167 1 Intergenic 
1 114630097-114675076 4 SYT6 
1 116717522 1 Intergenic 
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1 151792842-151817543 2 RORC, C2CD4D, THEM5 
1 161968072 1 OLFML2B 
1 175850011 1 Intergenic 
2 13134854 1 AC064875.2 
2 56002607-57936992 3 EFEMP1, CCDC85A, AC007743.1 
2 76944275 1 Intergenic 
2 137173396-137872490 2 THSD7B 
2 183699180-185281789 3 DUSP19, NUP35 
2 202847242 1 Intergenic 
2 207067503 1 GPR1 
2 212380286-213576272 3 ERBB4 
3 43794949 1 Intergenic 
3 45606651 1 LIMD1 
3 105695408 1 Intergenic 
3 112913318 1 Intergenic 
3 194538730 1 Intergenic 
4 4275260 1 LYAR 
4 99541944-99548762 2 TSPAN5 
4 100334943 1 ADH7 
4 107940588-107943491 2 DKK2 
4 135796170 1 Intergenic 
5 79086960 1 CMYA5 
5 99269809 1 Intergenic 
5 114127581 1 Intergenic 
5 118671874 1 TNFAIP8 
5 120965514 1 Intergenic 
5 147289856 1 Intergenic 
5 156626337 1 ITK 
6 21233412 1 CDKAL1 
6 25411435 1 LRRC16A 
6 27247668-27396321 3 POM121L2, VN1R10P, ZNF204P, ZNF391, MCFD2P1 
6 29937493-33853641 94 Major Histocompatibility Complex 
6 35337931-35732137 9 
PPARD, MKRNP2, FANCE, TEAD3, RPL10A, TULP1, FKBP5, 
ARMC12 
6 72805811-72828559 3 RIMS1 
6 106410424 1 Intergenic 
6 111924913 1 TRAF3IP2 
6 130512490-130537430 6 SAMD3 
7 8240341-8243193 3 ICA1 
7 20123972 1 AC005062.2 
7 22161810 1 RAPGEF5 
7 89333692 1 Intergenic 
7 141072134-141085654 3 TMEM178B 
8 72534277 1 Intergenic 
9 8710098 1 PTPRD 
9 24423134 1 Intergenic 
9 111621283 1 Intergenic 
10 56913475 1 PCDH15 
10 76833088 1 Intergenic 
10 79178467 1 KCNMA1 
10 94841988 3 Intergenic 
11 15169639-15177816 3 INSC 
11 73714650 1 UCP3 
12 28214312-28237731 4 Intergenic 
12 29659037 1 TMTC1 
12 58840232 1 Intergenic 
12 62396765 1 FAM19A2 
12 70951978 1 PTPRB 
12 79314798-79741443 3 SYT1 
12 83061803-83101314 3 TMTC2 
12 96544302 1 Intergenic 
12 102331085 1 DRAM1 
12 108703455 1 CMKLR1 
13 48726060 3 Intergenic 
13 69768976-69772154 1 Intergenic 
14 81127849 1 CEP128 
15 64185344 1 Intergenic 
15 77282884-77296134 3 PSTPIP1 
16 22943188 1 Intergenic 
16 57009165 1 CETP 
16 65902516 1 Intergenic 
16 72916326-73133159 3 ZFHX3 
16 85616985 1 RP11-118F19.1 (lincRNA) 
17 3496105 1 SHPK, TRPV1 
17 3498411- 3527281 2 SHPK, TRPV1 
17 3632836-3689132 3 ITGAE 
17 45316717 1 Intergenic 
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18 51448760 1 Intergenic 
19 38743962-38900106 14 
PPP1R14A, SPINT2, C19orf33, YIF1B, KCNK6, CATSPERG, PSMD8, 
SPRED3, GGN, FAM98C 
20 47403913-47420680 3 PREX1 
 
Supplementary Table 5: Regions under potential differential selection between cases 
and controls (absolute XP-EHH > 4). 
Chromosome Position No. SNPs Gene 
6 13824087 1 MCUR1 
6 31066671 1 Major Histocompatibility Complex 
6 53351289 1 GCLC 
7 53105223 1 POM121L12 
14 70875513-71047754 5 SYNJ2BP, ADAM21, ADAM20 
21 40093658 1 ERG, ETS2 
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Abstract 
Background: Genomic analyses of human populations tend to consider small variants, 
such as single nucleotide polymorphisms (SNPs) and insertion-deletions (indels), rather 
than larger structural variants (SVs) despite their established role in disease. With the 
recent development of sophisticated bioinformatic techniques for the detection and 
analysis of SVs, we are now able to conduct high-throughput, in-depth analyses of SVs. 
Such approaches allow for both the discovery of novel variants generally and, with the 
use of parent-child paired studies, confirmation of inheritance. 
Results: We present a comprehensive bioinformatic analysis of nearly 200,000 specific 
forms of putative structural variation within a human population of trios from Tanzania. 
6,932 of which are found in at least 5% of samples, 180,577 being found only once, and 
approximately 16.7% being inherited without mutation from parent to child. Those most 
frequent SVs include a heterozygous 4,136 bp deletion of SEC22B and its promoter, 
inversions of APP, and 2,494 bp deletions of ACSL3. We also highlight novel roles for 
structural variation in candidate genes associated with malaria risk and blood group 
antigen systems, including A4GALT, ATP2B4, and ABCG2. 
Conclusions: Our results demonstrate that SVs are present both broadly within the 
Tanzanian population and within specific genes with known roles in blood type antigens 
and risk of severe malaria. Inheritance of a notable portion of these variants suggests 
phenotypic roles that require investigation in the specific context of susceptibility to 
severe malaria and other communicable diseases. 
Keywords: Structural variation, genome diversity, African genomics, Tanzania  
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Background 
Large studies of global human genomics have led to the identification of variants 
associated with disease susceptibility and resistance phenotypes. Yet these studies have 
generally focused upon small variations, such as single nucleotide polymorphisms (SNPs) 
and insertion-deletion events (indels), whilst overlooking larger variation such as 
structural variants (SVs). SVs typically exist as deletions, duplications, inversions, and 
insertions or complex combinations of those, such as sandwich-inversions [1]. Naturally 
these large forms of variation can be highly disruptive, potentially knocking out a gene 
through deletion of its promoter or exons. Alternatively, they may enhance expression 
through whole gene duplication or sequence insertion. 
Established examples of structural variation in the human genome include duplications 
of AMY1 altering salivary alpha-amylase levels [2] and the 400 kb inversion of factor VIII 
causing haemophilia A [3]. Deletions of the Duffy antigen-encoding gene DARC have 
also been shown to convey reduced susceptibility to infection by the second deadliest5 
malaria parasite, Plasmodium vivax [4]. Given the global distribution of malaria, Duffy-
negative status is rare in Europe and the United States of America but present at relatively 
high frequencies across Africa [5].  
African populations are often under-represented in genomic analyses, including large-
scale endeavours such as the 1000 Genomes Project [6]. Tanzania represents one such 
population. Historically, African genomics tend to be less well understood than those of 
Europeans and North Americans, with the majority of genetic studies identifying disease-
relevant variants within Caucasian populations [7]. Several studies have also shed doubt 
on the validity of disease-association variants when in the context of non-Caucasian 
populations [8,9]. This includes SNPs that have been identified in association with an 
                                                 
5 As percentage of global deaths attributed to P. vivax. 
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increased risk of breast cancer and atrial fibrillation [10,11]. Together this highlights the 
need for a broader range of studies into human genomics such that local variations can be 
identified. 
Here we present a case-study analysis of structural variation derived from 156 human 
genomes collected from Tanzania, enhanced by inheritance analysis to their 78 
descendants, and focused towards the role of SVs in blood stage antigens. Whilst the 
majority of variants were rare, some genes include high frequency SVs with potential 
roles in intracellular transport, cell adhesion, and increased risk of severe malaria. 
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Results 
Overview of identified SVs 
Across the 156 parents 197,028 unique variants were identified across four forms of 
structural variation (deletions, duplications, insertions, and inversions) (Table S1) using 
a pipeline in which SVs were identified using DELLY and SV-Pop [12,13]. By type, this 
breaks down to 161,223 deletions, 17,543 duplications, 12,576 inversions and 5,686 
insertions. 19,139 distinct genomic features, including genes, enhancers, promoters, 
promoter flanking regions, and open chromatin regions, contain structural variants 
(deletions: 14,358; insertions: 3,004; duplications: 3,951; inversions: 2,054). In total, we 
identified approximately 2,514.7 variants per individual (1911.5 deletions, 128.5 
duplications, 365.8 insertions and 108.9 inversions), with those variants having a mean 
length of 3,537.7 bp (median 934 bp) (Table 1). Broadly, most SVs (59.7%) were inferred 
as being heterozygous with this being consistent across all models (deletions: 63.3%, 
duplications: 98.1%, inversions: 83.5%) except for insertions (20.0%). Fully inherited 
SVs tended to be more homozygous, as is to be expected, with only 29.1% being 
heterozygous.  
6,932 (3.5%) variants were present in at least 5% of parents, consisting of 5,151 deletions, 
1,555 insertions, 84 duplications and 142 insertions. 3,033 (43.8%) of these were 
completely intergenic, whilst the remaining 3,899 SVs (2,887 deletions, 876 insertions, 
53 duplications, 83 inversions) at least partially overlapped genomic features. 750 of 
those features were regulatory elements, including 56 transcription factor binding sites, 
176 promoter flanking regions, 80 promoters, 340 open chromatins and 98 enhancers 
(Table 1). 
Role of inheritance 
Detection of structural variants in both parent and child supports their validity and 
biological relevance. Per-parent a mean of 16.72% (range: 5.60% to 31.58%) of distinct 
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SVs were inherited without mutation. For the 53,730 instances of parent-child inheritance 
(of which there are 8,289 distinct SVs), the majority have at least one parent predicted as 
homozygous for the variant (Total: 69.9%, Homozygous/Homozygous: 15.0%, 
Homozygous/Heterozygous: 5.8%, Homozygous/Missing: 49.2%), whilst significant 
rates of heterozygous parents are also present (Total: 30.1%, 
Heterozygous/Heterozygous: 3.6%, Heterozygous/Missing: 26.5%). Insertions were 
proportionally more likely to be inherited, though this may be inflated by an inability to 
directly compare inserted sequences (Table S2). Those most frequently inherited variants 
generally mirrored the full parent dataset, with deletions of SEC22B, inversions of APP, 
and insertions in DNAH6 all being prominent. 
No significant ethnic stratification 
The Chagga, Pare, and Wasambaa ethnic populations display subtle differences in SV 
frequencies, with Pare (710.6 per sample, 13.7% inherited) having generally more 
variants (Kruskal-Wallis chi-squared = 5.001, P=0.08) and significantly lower rates of 
inheritance (Kruskal-Wallis chi-squared = 27.208, P=1.24x10
-6), than Chagga (557.4 per 
sample, 17.2% inherited) or Wasambaa (620.2 per sample, 18.7% inherited), though these 
differences were not large enough to suggest distinct ethnic stratification (Table S2). Of 
those differences, only one variant has an FST score greater than or equal to 0.2: an 
intergenic 328 bp deletion found at relatively high frequency in the Pare sub-group (FST: 
0.2, Tanzania: 17.95%, Chagga: 8.3%, Pare: 43.8%, Wasambaa: 5.0%). Conversely 657 
variants were proportionally identified for all sub-groups (FST = 0), including inversions 
within APP, TBC1D3, and LOH12CR1; deletions within ZNF665, ASIP, KCNB2, DKK2, 
ACSL3, MGAT5, SEC22B, and PDE4DIP; and duplications within AF146191.4, and 
NBPF1. For SV hotspots, five 1 kbp windows in two loci had an FST greater than or equal 
to 0.2. These included deletions within a promoter for the potassium channel KCNJ8 on 
chromosome 12 (FST: 0.2, Tanzania: 21.15%, Chagga: 0.0%, Pare: 47.9%, Wasambaa: 
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11.7%), and an intergenic region of chromosome X (Fst: 0.245, Tanzania: 11.54%, 
Chagga: 0.0%, Pare: 35.4%, Wasambaa: 1.7%). 
Window-based variant counts identify hotspots of variation 
Genome-wide window-based analysis identified 238,888 1 kbp windows (deletions: 
151,922, duplications: 46,976, insertions: 10,778, inversions: 29,212) where at least one 
individual had a structural variant (Figure 1). 62,779 of those windows contained variants 
for at least 5% of samples (deletions: 44,406, duplications: 8,663, insertions: 3,110, 
inversions: 6,600). 255 windows contained a variant for all parents, with 141 of those 
featuring deletions, and 114 featuring inversions. 
Deletion hotspots are found overlapping several genomic features including ACSl3, ASIP, 
DKK2, KCNB2, ZNF665, SEC22B and its promoter, three open chromatins 
(ENSR00000176649, ENSR00000181038, ENSR00000225923), a transcription factor 
binding site (ENSR00000195323), and 74 intergenic windows. In contrast, inversion 
hotspots include a 55,777 bp inversion on chromosome 17 centered on RP11-1407O15.2 
and its neighbouring features: TBC1D3, and open chromatin (ENSR00000093575), and 
a transcription factor binding site (ENSR00000093574) (Figure 2). 
Gene Ontology enrichment 
Enrichment analysis was applied to the most frequent variants (>5%) within the full 
parent dataset and identified 399 gene ontology terms (31 under-enriched, 368 over-
enriched) with a significant false discovery rate (<0.05) (Table S3). Enrichment fold 
changes ranged from 0.07 (immunoglobulin production (GO:0002377)) to 5.73 
(ionotropic glutamate receptor activity (GO:0004970)). 
In general, significant enrichment was observed for neural functions (synapse 
(GO:0045202): 2.07, FDR=1.69x10-13; neuron part (GO:0097458): 1.76, 
FDR=1.92x10-13), adhesion (cell adhesion (GO:0007155): 2.08, FDR=6.78x10-13; cell-
cell adhesion (GO:0098609): 2.43, FDR=1.14x10-10), and ion and drug binding (ion 
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binding (GO:0043167): 1.33, FDR=5.99x10-15, drug binding (GO:0008144): 1.57, 
FDR=1.42x10-8). Fold changes below 1 were present for terms relating to immunity 
(humoral immune response (GO:0006959): 0.19, FDR=3.27x10-5; adaptive immune 
response (GO:0002250): 0.41, FDR=1.31x10-3) and olfactory systems (olfactory 
receptor activity (GO:0004984): 0.36, FDR=1.96x10-3; detection of chemical stimulus 
involved in sensory perception (GO:0050907): 0.4, FDR=2.81x10-3). 
These enrichments were broadly reflected in the full variant dataset suggesting that they 
correspond to significant roles for structural variation in cell adhesion, neuro-synaptic 
biology, and drug binding contrasting with a minimal role in olfactory systems. One 
exception was immune response genes, which were only under-enriched in the frequent 
variants subset, suggesting that high frequency structural variants in immunological genes 
are actively selected against - perhaps due to hyper-variability. 
Structural variants associated with blood groups and susceptibility to malaria 
Given the broad scale of this study, we placed a specific focus on candidate regions 
previously associated with malaria or erythrocyte surface exposure to allow for a more 
in-depth, disease-relevant investigation. Malaria was selected due to its significant global 
impact, recent interest in identifying variants associated with susceptibility to severe 
subtypes, and our previous work using this dataset for imputation in a genome-wide 
association study within a severe malaria context [14].  
We considered structural variation for genes with established roles in malaria risk and 
blood antigen groups, of these 15 contained a structural variant in at least one parent 
(Table 2). Notable examples include A4GALT (which encodes the Pk antigen of the P 
blood group system), for which 17 individuals have a 369 bp deletion and 17 others have 
a heterozygous 700 bp deletion, ATP2B4 (malaria risk factor), for which 24 individuals 
have non-specific approximately 2,000 bp deletions, and ABCG2 (Junior (JR) blood 
antigen), for which 26 individuals have a 336 or 337 bp deletion (Figure 3). No structural 
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variants were identified in the Duffy gene, DARC, and a range of other blood group 
antigens including CD44, CD55, and ART4. None of these variants were fully inherited.   
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Discussion 
Structural variation underpins a wide range of genetic variation, but few large-scale 
investigations have been conducted, especially for African genomes. Endeavours such as 
the 1000 Genomes projects and the African Genome project have sought to better 
understand human genomics but tend to focus on smaller variants, such as SNPs and 
indels, and include only a limited range of African populations [6,15]. To our knowledge 
there has also been no specific consideration of the role of structural variation in blood 
antigen systems, or the impact of SV inheritance. 
We present an in-depth analysis of 156 Tanzanian parents, and further analysis of those 
variants inherited by their children (n=78). The characterisation of these variants is key 
to placing Tanzanian genomes within a global context and identifying novel variants. 
Broadly, the Tanzanian population considered here showed few signs of stratification, 
especially in relation to ethnicity. Structural variants also appear to be abundant, but 
actively selected against in most cases. This is consistent with previous studies that found 
an abundance of shorter and rarer variants, with a subset of variants being actively 
selected for [16–18]. 
The vast majority of structural variants were infrequent, with 91.65% of variants being 
present in only one individual. In contrast to the fully inherited variants that were found 
in a median of 55 individuals. This is consistent with structural variants generally being 
actively selected against with useful variants quickly being selected for. Broadly, 
enrichment is observed for gene ontology terms relating to cell adhesion, intracellular 
transport, and drug binding. Those variants that exist at higher frequencies within the 
Tanzanian population tend to be deletions, though this is unsurprising given that they are 
the most common form of variant. 
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Whilst most SVs are non-specifically conserved in the general Tanzanian population, 
several genes contain specific variants that appear to have become fixed, or near-fixed, 
relative to the human reference genome. The most striking examples include a 
heterozygous 220 bp deletion in BET1L (98.7%), a gene associated with ER-Golgi vesicle 
transport-associated BET1 [19], and a 4,136 bp deletion in SNARE-complexing SEC22B 
(98.7%) [20]. Notably BET1 and SEC22B both have roles relating to SNARE 
functionality in the ER to Golgi transportation [21,22], suggesting that deletions in 
SEC22B and BET1L may have a linked phenotypic impact. Similar deletions have also 
been identified in samples from Nigeria, North America, and Kuwait, suggesting 
widespread pseudogenisation of these genes [23–26]. Several other SVs are also present 
within genes that encode surface-exposed proteins, such as GPR156 (probable G-protein 
receptor, 29 bp insertion in 77.6%), and TSPAN8 (2,117 bp deletion in 72.4%). 
Our focus on known malaria risk factors or blood group antigen genes led to the 
identification of SV hotspots in Pk antigen gene A4GALT, malaria risk factor ATP2B4, 
and JR blood system antigen ABCG2, amongst others. Many of these have been identified 
in broad studies of structural variation in several populations, though without phenotypic 
context or specific investigation [23,24,27]. Interestingly, ABCG2 encodes a transporter 
protective against xenobiotic molecules as well as the antigen of the JR blood system 
[28,29]. The wild type Jr phenotype is found at high prevalence in all populations whilst 
the Jr(a-) phenotype is a highly rare variant found, for example, in 0.05% of Japanese 
blood donors [30]. Whilst null variants of ABCG2 can be caused through various short 
variants [30], it is unclear whether the 336/7 bp deletions detected here reflect a rare JR 
phenotype. 
Several high frequency SVs are also present within genes that have been otherwise linked 
to potential roles in malaria susceptibility and other diseases. For example, 84.6% of 
parents have a 40 bp insertion in RAB7A, a key regulator of endosomal trafficking [31], 
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with a similar insertion being present within the Venter genome [27]. RAB7A has been 
found in P. berghei-containing host vesicles [32] and is a known target for microbial 
survival strategies, such as with Salmonella, further supporting its role in general host-
pathogen interactions [33]. Our identified insertion may therefore convey a protective 
effect, inhibiting Plasmodium invasion or intracellular survival. 
Notably, all sampled genomes were aligned to the GRCh37 version of the human 
reference genome, which was sourced from 13 anonymous individuals in New York [34]. 
As such, many of the structural variants identified in this study may represent fixed, silent 
population differences between American and African genomes rather than recently 
selected variants, although many such selection events likely exist. 
Conclusions 
Several novel structural variants were detected within the Tanzanian population, some of 
which may have roles in intracellular transportation, cell-cell adhesion, and blood 
antigens. The vast majority of variants were rare, though a significant number were near-
fixed or inherited without mutation from parent to child. Our findings are consistent with 
previous studies that suggest structural variants are frequent to occur, but experience 
limited positive selection. This work highlights the importance of continued, high-
throughput discovery in further populations.  
165 
 
 
Methods 
Dataset composition, collection, and sequencing 
Our dataset included 247 anonymously sampled individuals, consisting of 78 healthy 
parental and child trios (156 parents, 78 children); 80 Chagga, 77 Pare, 90 Wasambaa 
(Parents: 48 Chagga, 48 Pare, 60 Wasambaa)). 13 singletons were also present but 
excluded from primary analysis. Samples were collected between 2007 and 2008 villages 
near the Kilimanjaro, Pare, and West Usambara mountains in the Tanga region of 
Tanzania, a region with a low to medium level of malaria transmission. Preliminary 
candidate region structural variation analysis was previously conducted to compliment a 
genome-wide association study [14]. Samples were sequenced at the Sanger Institute 
using Illumina HiSeq2500 technology and aligned to the GRCh37 build of the human 
genome. All co-ordinates refer to the GRCh37.p13 build of the human genome, with 
annotations being acquired from NCBI. 
Variant Identification and Filtering 
Structural variants were identified using DELLY version v0.7.3 with default parameters 
[12]. High-throughput, post-discovery filtering and analysis was undertaken with SV-Pop 
version 1.0 [13] (available at http://github.com/mattravenhall/SV-Pop) and through 
manual curation. Variants were removed for overlapping known assembly gaps, being 
abnormally long (>100,000 base pairs), and according to population-level DELLY scores 
including quality (mean < 0.9), inferred percentage homozygous reference (>10%), and 
inferred percentage homozygous missingness (>10%). SV discovery was performed for 
parent and child groups separately, with the inherited subset being those found for both 
parent and children without inter-generational mutation. Regional hotspots were 
identified with SV-Pop using default parameters consisting of a sliding window count for 
a 1000 bp window with a 500 bp step. 
Gene Ontology 
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Gene ontology analysis was performed separately for the parent variants and frequent 
parent variants (>5%) datasets using the PANTHER classification system [35]. 
Significance was defined as a false discovery rate less than 0.05. 
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Figure & Table Legends 
Table 1: Summary statistics of identified structural variants by model. 
Variant 
Type 
Total 
Count 
Mean per 
Sample 
Length 
(median bp 
(range)) 
1 kbp 
Windows 
Frequent 
(>5%) 
Intergenic Genic 
Deletions 161,223 1,911.5 
954 (13 to 
99,429) 
151,922 5,151 64,078 97,145 
Duplications 17,543 128.5 
958 (138 to 
99,894) 
46,976 84 6,855 10,688 
Insertions 5,686 365.8 21 (15 to 138) 10,778 1,555 2,382 3,304 
Inversions 12,576 108.9 
1,261 (95 to 
99,999) 
29,212 142 4,588 7,988 
 
Table 2: Specific forms of structural variants associated with malaria risk or blood 
antigen genes. 
Gene Qualification Location Total Deletions Duplications Insertions Inversions 
A4GALT 
P blood system 
(Pk antigen) 
22: 43,088,127-
43,117,304 
31 31 - - - 
ATP2B4 
Malaria risk 
factor 
1: 203,595,689-
203,713,209 
24 24 - - - 
ABCG2 Jr blood group 
4: 89,011,416-
89,152,474 
22 22 - - - 
FREM3 
Malaria risk 
factor 
4: 144,498,455-
144,621,828 
21 21 - - - 
AQP1 Colton antigen 
7: 30,893,010-
30,965,131 
11 11 - - - 
GYPC 
Gerbich blood 
group 
2: 127,413,509-
127,454,246 
4 4 - - - 
RHD Rh Protein 
1: 25,598,884-
25,656,936 
3 - - - 3 
RHCE Rh Protein 
1: 25,688,740-
25,756,683 
3 - - - 3 
ABO 
ABO blood 
group 
9: 136,125,788-
136,150,617 
2 1 - 1 - 
XG XG antigen 
X: 2,670,091-
2,734,539 
2 1 - 1 - 
XK Kx antigen 
X: 37,545,012-
37,591,383 
2 2 - - - 
GYPB MNS antigen 
4: 144,917,257-
145,061,844 
1 1 - - - 
SLC14A1 Kidd antigen 
18: 43,304,092-
43,332,485 
1 1 - - - 
C4B 
Chido/Rodgers 
antigen 
6: 31,982,539-
32,003,195 
1 1 - - - 
BSG Ok blood group 
19: 571,297-
583,493 
1 - - 1 - 
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Figure 1: Coverage plot confirming the 4,136 bp heterozygous deletion in SEC22B. 
Blue represents the per base coverage, Orange indicates the predicted structural variant, 
Green indicates the gene of interest, Grey indicates genomic features including genes 
and enhancers. 
 
 
Figure 2: Coverage plot confirming the 336/7 bp deletions in ABCG2. Blue 
represents the per base coverage, Orange indicates the predicted structural variant, 
Green indicates the gene of interest, Grey indicates genomic features including genes 
and enhancers. 
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Supplementary Figure & Table Legends 
Supplementary Table 1: Full list of putative structural variants. [large file] 
Supplementary Table 2: Per-sample ethnicity, model, and inheritance. [large file] 
Supplementary Table 3: Significantly enriched gene ontology terms. [large file]  
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Chapter 7: 
SV-Pop: Population-based structural variant analysis and 
visualisation 
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Chapter 8: 
Discussion, Conclusions, and Future Work 
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8.1 Discussion 
The work presented here combines two similar approaches to identify and characterise 
novel genomic variation relevant to host-pathogen interactions in malaria, one focused 
on the P. falciparum parasite and the other on their human hosts. Both components began 
with single context studies primarily exploring SNP-based variation, with the 
incorporation of selection methods and candidate structural variation (Chapters Two and 
Five). Having identified some key novel structural variants when using a candidate gene 
approach, both human and parasite components progressed to large-scale explorations of 
structural variation either globally (Chapter Three), in long-read assemblies (Chapter 
Four), or with consideration of inheritance (Chapter Six). These SV-based studies 
required the development of novel pipelines and software as detailed in Chapters Four 
and Seven. 
 
Beginning with the parasite component, Chapter Two covers my work investigating the 
impact of sustained SP use on the Malawian P. falciparum population following fourteen 
years of primary use following a switch from chloroquine in 1993 and to ACTs in 2007 
[1], with those samples being collected between 2010 and 2012. Perhaps unsurprisingly 
a high frequency of SP resistance associated SNPs remained within the population, with 
these including classic variants such as dhps double mutants (A437G and K540E, 99.5%) 
and dhfr triple mutants (N51I, C59R, and S108N, 97.7%). SNPs associated with 
chloroquine resistance were entirely absent, suggesting that the P. falciparum population 
was generally chloroquine susceptible, consistent with the existing literature [2]. 
 
These SNP-based findings were supported by signals of selection, as demonstrated by 
extended haplotype homozygosity-based approaches. Within the Malawian population, 
significant recent positive iHS selection signals were observed around dhps, dhfr, and 
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gch1, reinforcing their roles in SP resistance [3]. Additional iHS signals, suggestive of 
conserving selection, were observed around ama1, trap, and rrf1, all of which encode 
surface antigens crucial for erythrocyte and hepatocyte invasion [4,5]. Relative selection 
signals between Malawi and other regions were also considered, with signals for Malawi 
around gch1, dhps, and acs8 (acyl-coA synthase), and for non-Malawi around crt, trap, 
and msp10. Relative selection for gch1 and dhps is consistent with positive selection in 
Malawi due to SP pressure, which neighbouring countries lack. Similarly, the reverse is 
true for crt, as chloroquine use was halted early in Malawi [1]. Relative selection 
elsewhere for the merozoite surface protein msp10 is more curious and may underpin 
regional differences in host-pathogen interactions. Structural variation was also 
considered for candidate resistance genes, given the present of gch1 duplications in 
Southeast Asia [6]. Those whole gene duplications were found at a low frequency in 
South (11.1%) and Southeast Asia (7.6%), but absent from Malawi. Instead, novel 436 
bp duplications were identified immediately upstream of gch1 within a probable TATA 
box, suggesting a potential role in the expression of gch1. 
 
For the human component, Chapter Five describes my initial focus on a genome wide 
association study for a Tanzanian population (n=914) to identify SNPs associated with 
susceptibility to, or protection against, severe malaria subtypes, such as respiratory 
distress or cerebral malaria. This dataset included individuals from malaria-endemic 
regions, divided into those who had experienced a severe response to malaria infection 
(case), and those who had not (control). This case-control approach confirmed the 
association of the sickle polymorphism rs334, and identified novel associations including 
a pair of interleukin receptors IL-23R and IL-12RBR2. Together these suggest a potential 
role for pro-inflammatory cytokines in severe responses to malaria which may be linked 
to previous studies that found a protective role for IL-12 and IL-23 [7,8]. Crucially those 
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novel SNPs found in association with severe subtypes were subtly different to variants 
found in other populations, this being consistent with other GWASs that have identified 
population-specific associations [9,10]. Many of these variants likely reflect SNPs within 
local haplotypes that carry a causal variant, or causal variants that are not under strong 
selection in other populations. As with the Malawian P. falciparum approach in Chapter 
Two, signals of selection were detected using EHH-based iHS and XP-EHH. In this 
context, iHS considered selection in the combined population, whilst XP-EHH considered 
selection differences between the case and control group. Due to the high level of 
relatedness within this dataset, XP-EHH signals were generally low but differential 
selection signals were identified in SYNJ2BP, GCLC, and the MHC. Selective differences 
within the MHC were expected given its key immunological role, however relative 
selection for SYNJ2BP, which encodes a membrane trafficking protein, suggest possible 
roles in parasite invasion of liver or red blood cells that require laboratory confirmation. 
Candidate SV discovery was also considered for genes with the most significant 
association or selection signals, with this work being expanded upon in Chapter Six. Here 
a range of low frequency SVs were identified and imputed into the primary GWAS 
dataset, with no SV being significantly associated with risk of severe subtypes. 
 
As my project progressed, the impact of larger structural variation became more apparent, 
so I sought to conduct large-scale discoveries of SVs in both parasite and human 
populations. Chapter Three focused on global differences in the distribution of structural 
variation in 3,110 P. falciparum samples from 21 malaria-endemic countries. Over one 
million putative structural variants were identified, with this being filtered to a high-
quality subset of >70,000 specific deletions and >600 duplications. The majority of 
specific variants were rare (48.5% of deletions and 94.7% of duplications are found in 
single isolates), only 2.4% of deletions and 0.2% of duplications found in at least 5% of 
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samples. This study allowed for a greater resolution for the global distribution of 
previously identified duplications of mdr1 and the gch1 promoter region, the latter 
initially being discovered in the work described in Chapter Two. This confirmed mdr1 as 
a primarily Southeast Asian duplication, and the gch1 promoter duplication as focused 
within Malawi but also present in several Central and East African populations. A novel 
22.9 kbp duplication of crt was also identified in West African samples primarily from 
Burkina Faso and Ghana, but also Guinea and Mali. This large crt duplication is 
particularly intriguing as it displayed high rates of diploid-type phasing, here being used 
as an approximate proxy for mixed infections in the haploid samples. Follow up 
haplotype-based analysis of the specific sequencing reads present for the region found 
high conservation for reads containing both the chloroquine resistance and susceptible 
types of crt. This suggested the presence of two copies of crt, one wildtype and one 
conveying chloroquine resistance. Regional concordance between species, and 
consistency in the read count ratios (1:1) for chloroquine resistant and susceptible types 
mean that this in silico finding is highly robust. Presumably, carriage for both chloroquine 
resistant and susceptible forms of crt allows the benefit of both phenotypes, perhaps 
‘locking in’ chloroquine resistance whilst accounting for associated fitness costs. This 
reflects similar hypotheses for the role of gch1 whole gene, and presumably promoter, 
duplications. By producing more GCH1, resistant but less efficient forms of DHPS and 
DHFR may have their fitness costs counter-balanced, whilst two forms of crt may allow 
for the expression of a more efficient wildtype CRT alongside or instead of a resistant 
alternative. 
 
Through investigating the use of short read-based approaches for the inference of 
structural variation, it became apparent that some types of SV were less successfully 
identified than others. Specifically, inversions have been poorly detected and 
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characterised in P. falciparum despite several variants of interest, such as the inversion-
duplication of gch1 in Dd2 [11]. To tackle this, I sought to develop a basic method for 
inversion detection which utilised long sequencing reads. In theory, longer sequencing 
reads such as PacBio and Nanopore should be able to identify variants in highly similar 
or repetitive regions more accurately than short read-based methods [12].   
Chapter Four details the development of a long-read alignment-based pipeline for the 
identification of inverted sequences relative to the 3D7 reference genome. Many of the 
inversions detected in this study were present within highly variable var, rifin, and stevor 
genes or intergenic regions that are often excluded from short-read based SV discovery 
due to difficulties resolving their sequences. The abundance of inversions in these highly 
variable regions is consistent with the existing literature and probably relates to the highly 
variable nature of these genes [13]. The presence of ancestral inversions was another key 
finding, with key examples including the P. falciparum unique rh2a/b gene pair and a 
pair of elongation factors 1-alpha [14]. Phenotypically these are likely to be well 
established and highly conserved but highlight inversion-deletions as a key combination 
of structural variants. Similarly, ‘sandwich inversion’, in which a sequence exists inverted 
between two other copies are a feature previously identified for gch1 in the lab-derived 
Dd2 strain of P. falciparum [11]. Alongside robustly discovering that feature in Dd2, a 
novel ‘sandwich inversion’ of pi4k in GB4 was identified. In this variant, the second 
(inverted) and third copies of pi4k appear to contain truncating mutations or partial 
deletions, likely leading to a complete loss of function. It therefore seems unlikely that 
this variant produces an increase in relative PI4K expression but perhaps demonstrates a 
process of pseudogenisation whereby PI4K expression has been lost for all three copies. 
PI4K itself is of interest as it is the target of imidazopyridines [15], loss of expression 
may therefore represent an emerging form of resistance. 
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In contrast, the study described in Chapter Six considered structural variation in 78 trios 
from malaria endemic Tanzania with a focus applied to genes with known associations 
with risk of severe malaria and roles in blood antigen systems. I also took this opportunity 
to explore the role of inheritance in structural variation, finding that approximately 16.7% 
of each parent’s specific structural variants were present without mutation in their 
children. Broadly, SVs were diverse, but rare, with 91.7% of specific forms being found 
only once. This low frequency partially reflects uncertainty around the specific position 
of SVs but is also consistent with active selection against most variants, as has been 
observed in other studies [16]. Nonetheless a few variants are present at near-fixation 
suggesting previous selective pressure for these variants. In total only 0.17% (n=328) of 
variants were found in at least 50% of parents. These include several genes with roles in 
cell adhesion, intra-cellular transport, and drug binding. Notable examples include 
SEC22B and BET1, both of which have significant roles in trafficking from the 
endoplasmic reticulum to the Golgi complex [17,18]. Additional focus was placed on 
genes with known roles in blood antigen systems or risk of severe malaria, leading to the 
identification of SVs in the Junior blood group antigen encoding ABCG2, the Pk antigen 
forming A4GALT, and malaria risk associated ATP2B4. Without phenotypic data for the 
individuals utilised in this study, it was not possible to link these SVs with any specific 
diseases or phenotypes, though their identification should initiate candidate exploration 
within the field or laboratory. 
 
In general, the exploration of SVs in the P. falciparum and human genomes both 
identified many rare variants, the majority of which were deletions. A number of these 
possible constitute false positives, which I sought to filter out via concordance in both 
detection methods and independent samples. Notably insertions and inversions were 
excluded from the P. falciparum SV project in Chapter Three due to significant levels of 
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noise within those datasets. In general, the core detection method, DELLY, was more 
robust for the diploid human genome rather than the haploid P. falciparum genome. This 
distinction is also key to understanding the different uses of predicted phasing scores in 
both studies. In Chapter Six, phasing is a classic prediction of the dosage for each SV 
however in Chapter Three it represents a proxy for cryptic mixed infections or poorly 
resolved loci, as heterozygous status should not be possible for a clonal sample of a 
haploid species such as the blood stage P. falciparum. This hints at the potential for SV-
based mixed infection detection methods, similar in approach to existing SNP-based 
methods such as estMOI [19]. One exception to filtering by predicted phasing was for 
duplications within P. falciparum where the duplication was imperfect, here two copies 
of a duplication may be assumed as heterozygous when they are highly divergent. This is 
best demonstrated with crt, where divergence between the two copies was supported by 
haplotype inspection. 
 
Both Plasmodium and human focused branches of my work highlighted the poor scaling 
of existing SV discovery methods, so I sought to develop a method to facilitate multi-
population investigation of structural variant in large sample sets. This method is 
introduced in Chapter Seven in which I highlight the analysis and visualisation 
components of the project, but partially underpins the work features in Chapters Three 
and Six. SV-Pop consists of two components; an analysis module and a visualisation 
model. The analysis module takes in structural variants predicted from several discovery 
methods, integrates population level metadata, and applies both population-based filters 
and statistical methods on those groups to enhance validity. Those variants can then be 
passed to the visualisation module, which allows population-population comparison and 
integration of statistics such as fixation indexes (FST). All metadata is inferred from the 
inputs provided, reducing the need for manual refinement and allowing the user to jump 
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straight towards interpretation. The visualisation module can also be used as the 
foundation for web resources should the user wish to share their dataset with the wider 
scientific community. 
 
8.2 Conclusions 
Host-pathogen interactions between P. falciparum parasites and their human hosts are 
underpinned by a range of genomic variation, from single nucleotide polymorphisms to 
large structural variants. Much focus has been placed upon SNPs, and less on SVs, despite 
potentially comparable impacts. The work presented here goes some way towards 
highlighting the need for high-throughout, large-scale investigations of structural 
variation, as currently occurs for SNPs, and developing methods that facilitate it. It also 
demonstrates that large genomic changes can be geographically specific, and therefore 
potentially used in species barcoding alongside SNPs. 
 
For the P. falciparum parasite, the work described in Chapter Two, emphasised the ability 
for chloroquine resistance to be eliminated from a population once that anti-malarial is 
removed, raising the potential for carefully managed rotations of antimalarials to combat 
rising resistance. However, the persistence of SP resistance traits several years after the 
switch to artemisinin-based combination therapies suggests that rotation may not be 
suitable for all drugs, with some forms of resistance persisting even after the removal of 
the associated treatment. Novel structural variants were identified that may directly 
convey antimalarial resistance or compensate for the fitness costs of other resistance 
variants. Duplications of the gch1 promoter and the region including crt represent 
significant novel variants that require experimental follow up. Inversions were also 
explored, with several novel forms potentially conveying resistance. The most significant 
example of this is the sandwich inversion of pi4k in a GB4 sample, which may represent 
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a disruptive, rather than enhancing, feature given its association with multiple nonsense 
mutations. Many of these novel findings may help inform future drug recommendations, 
for example advising against SP use in regions with high levels of the gch1 promoter 
duplication if it is found to increase parasite resistance. 
 
For the human studies, SNP associations beyond the well-established examples, such as 
rs334, were rare and potentially unique to Tanzanians. Key associations were identified 
between IL23R and IL12RBR2 that suggest a novel, possibly local, immunological 
protective effect. In general, those variants identified in the GWAS likely reflect both 
variants of reduced impact, and local responses to specific Plasmodium populations. For 
SVs, many forms exist with only a few being actively selected for. Those at high 
frequency feature robust signals and exist in roles relating to cell adhesion, intracellular 
transport, and blood group antigens. Here significant findings were deletions in SEC22B 
and BET1L, both of which imply a role in intracellular trafficking from the endoplasmic 
reticulum to the Golgi complex, and in ABCG2 which may underpin the rare Jr(a-) blood 
type. Together these findings may help inform resource allocation by identifying 
populations at risk of severe response to malaria infection. 
 
8.3 Future Work 
Being a primarily computational body of work, there is a clear need for laboratory 
exploration of the variants identified here. Prime examples include the 436 bp gch1 
promoter duplication, sandwich inversions of pi4k in GB4, and SEC22B deletions in 
Tanzania. The 436 bp gch1 duplication is particularly striking as it appears at near fixation 
in Malawi, whilst also being present at significant frequencies across several other Central 
(Democratic Republic of Congo 26.3%) and East African populations (Tanzania 78.5%, 
Kenya 31.6%). PCR confirmation of the duplication, and its specific structure, is required 
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to confirm this finding in vitro. Given the role of gch1 in the folate pathway, associations 
of its duplication with SP resistance, and the heavy use of SP in Malawi, it seems likely 
that this promoter duplication would also be associated with SP resistance. If duplication 
of the promoter leads to increased expression of the protein, as it likely with gch1 
duplication, this provides a phenotype of compensation for fitness costs associated with 
dhps and dhfr mutations which can be experimentally validated. If mutations within dhps 
and dhfr genes are associated with reduced efficacy of those proteins, duplications 
associated with gch1 may ensure that sufficient levels of folate are produced. Naturally 
this cannot be properly investigated in silico, so classic laboratory-based exploration of 
the impact of gch1 promoter duplication on gch1 expression, for example qPCR 
comparisons with mutant strains containing zero, one, two or more copies of the promoter 
region to determine their effect on levels of gch1 transcription , should be undertaken. If 
gch1 expression is found to compensate for dhps and dhfr mutations, duplications may 
relate to late-stage ‘locking in’ of SP resistance that would need to be included in active 
surveillance given the critical role of SP in intermittent treatment of pregnant women and 
of children (including seasonal malaria chemoprevention). 
 
Another novel duplication identified in silico is the putative heterogeneous duplication of 
the chloroquine resistance transporter, crt. Here we find a striking signal in West Africa, 
and particularly Burkina Faso, where a large 22.9 kbp duplication appears to contain two 
different forms of the crt gene in tandem, one being wildtype and one containing the 
chloroquine-resistance associated K76T mutation. Given the tendency for K76T to leave 
Plasmodium populations following the removal of chloroquine use, as shown in Malawi 
but also elsewhere previously, it seems likely that the variant conveys a fitness cost. The 
presence of two copies of crt, one conveying resistance and being beneficial in a 
chloroquine-rich environment and the other being wildtype and more beneficial in a non-
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chloroquine environment, might suggest a compensatory mutation for that fitness cost. 
Again, follow up classic laboratory work is crucial for characterising this variant, with 
targeted PCR sequencing being applied to better understand the specific local sequence 
and its breakpoints, and competition assays to compare the impact of carrying both K76T-
positive and K76T-negative copies of crt against wildtype and K76T-positive strains in 
the presence or absence of chloroquine. Tagging of those proteins is also key to 
determining whether the pair are expressed in parallel, therefore producing heterogeneous 
expression of CRT, or in response to the presence of chloroquine, suggesting the presence 
of a potentially novel and complex response to antimalarial detection by the parasite. 
Once better understood, surveillance of this duplication would need to be undertaken 
particularly as the presence of both K76T-positive and K76T-negative sequences may 
cause false positives for studies and diagnosis tests which test for the K76T-negative 
sequence. 
 
Several novel human variants were also identified in Tanzania, with some being 
associated with blood antigen and malaria risk genes. These all require follow up 
confirmation, perhaps through PCR sequencing or additional in silico detection, and 
functional characterisation before further clinical work can be considered. Examples 
include the 336/7 bp deletions in ABCG2, the gene encoding a xenobiotic transporter and 
the JR blood antigen. Smaller nonsense mutations have been shown to cause the highly 
rare JR(a-) phenotype [20], and it seems likely that larger deletions could produce a 
similar phenotype. If so, there may be associations of Jr(a-) status with malaria or similar 
blood-borne diseases. The GWAS approaches utilised here can also be enhanced through 
the imputation of further putative SVs, and a move towards a host-pathogen paired-
genome analysis. This would require the sequencing of both individuals and the parasites 
they are infected with. Sequencing both species allows for variation between infecting 
192 
 
 
parasites, perhaps even for mixed infections, and between human hosts to be adequately 
controlled for. This would therefore provide additional statistical power for the detection 
of further novel significantly associated SNPs. 
 
These broad structural variant discovery approaches clearly identify a wealth of novel 
variants in significant genes. The development of SV-Pop has paved the way for other 
multi-population studies of structural variation. One clear next step is to perform the 
approaches utilised in Chapters Three and Six for other Plasmodium species, such as P. 
vivax and P. knowlesi, and for further human populations. Chapter Seven lays the 
groundwork for future analysis and exploration of global structural variation of this sort. 
The same can be said for inversion discovery, as described in Chapter Four, using long-
read based assemblies with larger population datasets. Exploration of these datasets, 
particularly using the SV-Pop visualiser, may help identify further copy number variants 
with key roles in anti-malarial resistance, host susceptibility, or other disease-relevant 
phenotypes. Any future studies should seek to integrate advances in long-read based 
approaches; methods for their utilisation, such as the pipeline described in Chapter Four, 
therefore need to be actively developed.  
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